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Acute myocardial infarction (AMI), also known as a heart attack, is a prevalent 
cardiovascular disease and a major cause of hospitalisations and deaths [1-3]. 
AMI reflects the loss of cardiac tissue as a result of prolonged ischemia that 
originates from an imbalance between blood supply and demand [4]. Ultimately 
this will result in the manifestation of symptoms such as chest pain and 
dyspnea. Blood supply is typically decreased because of a ruptured 
atherosclerotic plaque in the coronary arteries (coronary artery disease; CAD), 
subsequently forming a thrombus that can occlude the coronary blood vessel 
(FIGURE 1). However, also conditions other than CAD can provoke myocardial 
damage and AMI, such as coronary vasospasms, endothelial dysfunction and 
revascularization procedures.  
 
 
 
FIGURE 1. Representation of normal coronary arteries in a healthy heart (A) and the presence of coronary 
artery disease (CAD) leading to acute myocardial infarction (AMI) (B). 
 
Cardiac biomarkers are an essential component of the diagnostic criteria for 
myocardial infarction [4]. Ideally, to make a correct and early diagnosis, a 
cardiac biomarker should be heart specific and early detectable in the patients’ 
blood [5]. Many previous biomarkers (such as creatine kinase and lactate 
dehydrogenase) have the disadvantage that they are not solely expressed in the 
heart. Therefore, in the early 1990s, the search for a better cardiac biomarker 
has led to the discovery of cardiac specific isoforms of troponin T (cTnT) [6, 7]  
and troponin I (cTnI) [8].  
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(Patho-)physiology of cardiac troponins 
Troponins are components of the sarcomeres, where they regulate the 
contraction and relaxation of muscle tissue [9] (FIGURE 2). They are composed 
of three subunits: troponin T, which anchors the protein-complex to 
tropomyosin; troponin I, facilitating the binding of myosin heads to actin strains; 
and troponin C, the calcium-binding subunit that initiates muscle contraction. 
Troponins T and I both have a unique isoform that is exclusively expressed in 
cardiac muscle (cTnT and cTnI, respectively), whereas troponin C (TnC) has 
not. Structural characterisation of cTnT and cTnI revealed two elongated 
proteins with a relatively low molecular weight of approximately 38 kDa and 24 
kDa, respectively [9, 10]. 
 
FIGURE 2. Physiology of the healthy myocardium. The myocardium is composed of bundles of myofibrils, 
which in turn are comprised of repeating units of sarcomeres. Subsequently, each sarcomere contains 
myosin and actin filaments which are bound at regular sites to the cTnT-I-C complexes.  
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Within the cardiomyocytes, cardiac troponins (cTn) are complexed with the 
cardiac myofibrils, although there is some evidence for a smaller soluble fraction 
(5-10% of total cTn amount) in the cytoplasm [11-13]. Recently, it was shown 
that this cytosolic fraction is probably not a fixed percentage, but may depend 
on a seemingly reversible binding between cTn and myofibrilar proteins [14]. 
Also, in vitro studies have demonstrated that the presence of unbound cTnT 
induces cytotoxicity to the cardiomyocytes [15], questioning whether such 
soluble fractions truly exists. 
Ischemic damage to cardiomyocytes causes increased cell permeability and 
necrosis, resulting in a rapid release of cTn molecules into the patients’ blood 
circulation (FIGURE 3).  
 
 
 
 
 
FIGURE 3. Following myocardial damage, cardiac troponins are released into the patients’ blood stream. The 
cTn proteins can be measured in blood samples collected from the patient. 
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Once released into the blood, cTnT and cTnI can be measured using antibody-
dependent assays (FIGURE 4). Serial cTnT measurements in AMI patients’ 
sera reveal a distinct biphasic release pattern. This cTnT-curve initially displays 
a rapid increase in just a few hours after AMI, and a second prolonged elevation 
or plateau phase in which cTn concentrations remain abnormal for up to two 
weeks [11, 16, 17]. It is hypothesized that the initial release originates from the 
cytosolic cTnT pool, which are easily released into the blood circulation [11, 13]. 
The sustained cTnT concentrations are presumed to be the result of slower 
release of myofibril-bound cTn molecules. In contrary to cTnT, cTnI 
concentrations more rapidly decreases after reaching peak concentrations, 
resulting in a monophasic release curve [17]. 
 
 
 
 
FIGURE 4. Measuring principles of cTnT and most cTnI assays. Generally, circulating cTn proteins in the 
patients’ blood are captured and detected using antibodies specifically directed against cTn. Serial cTnT or 
cTnI measurements in AMI patients’ blood result in a biphasic or monophasic release curve, respectively 
(PROTECT study, Maastricht University Medical Center, unpublished data). 
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Ischemia is also known to activate proteolytic enzymes that can result into post-
translational modifications of cTnT and cTnI proteins, such as phosphorylation 
and degradation [18]. A heterogeneous mixture of molecular forms of cTnT and 
cTnI proteins have been characterized in the blood of AMI patients [5]. For cTnI, 
free and complex forms with TnC (cTnI-C complex) and to a lesser extent with 
cTnT (cTnT-I-C complex) were observed [19-21]. Also fragments of cTnI as well 
as cTnT have been described [16, 22, 23]. Although the presence of cTnT 
fragments were strongly disputed by Bates and colleagues, who found cTnT to 
mainly circulate in the intact free form [24]. Whether cTnT fragments are present 
in the patient`s circulation therefore remained a matter of debate. 
Cardiac troponin as the diagnostic biomarker for acute myocardial infarction 
According to consensus documents of multiple international societies in 
cardiology [4, 25, 26] and biochemistry [27, 28], cTnT and cTnI are since 2000 
the preferred biochemical markers to diagnose AMI because of their tissue 
specific expression in the myocardium. In addition, they should be accompanied 
with clinical symptoms or imaging signs of ischemia, that can be assessed by a 
number of different means such as physical examinations, changes on 
electrocardiography (ECG) and imaging evidence of new loss of viable 
myocardium [4]. AMI patients can be subdivided according to the presence or 
absence of ST-elevation on the ECG, resulting in ST-elevation MI (STEMI) and 
non-ST-elevation MI (non-STEMI). Because of the absence of ECG changes, 
NSTEMI is more difficult to diagnose and mainly relies on the presence of  
elevated cTn concentrations [6, 29]. 
The diagnostic cTn cutoff for myocardial infarction was set at the 99
th
 percentile 
upper reference limit (URL) of a healthy reference population (FIGURE 5) [25]. It 
was presumed that the amount of false positives is minimized in this way, as it is 
more common for other biomarkers to use the 97.5
th
 percentile URL. The 
diagnostic cutoff should also be measured with sufficient precision, preferably 
not exceeding a 10% coefficient of variation (CV) for the cTn assays although 
up to 20% CV remains clinically acceptable [28, 30]. 
The cTnT assay is produced by a single manufacturer, while multiple 
companies (>10) market cTnI assays. Each manufacturer uses different 
CHAPTER ONE 
14 
 
antibody pairs [31], resulting in variable assay results [32]. Due to the 
heterogeneity in cTnI assays, it is strongly endorsed for each assay to report 
their own 99
th
 percentile concentration [33].  
 
 
 
FIGURE 5. Illustration of the 99th percentile cTn concentration of a reference population of healthy 
individuals, used as the diagnostic cutoff for AMI. 
 
 
The era of high-sensitivity cardiac troponin assays 
At the time that the 99
th
 percentile cutoff was defined, none of the commercially 
available cTn assays were able to measure this concentration with sufficient 
precision (<10% CV) [32, 34]. Ongoing improvements in technology over the 
past several years have advanced the analytical detection of cTn in the blood, 
permitting the detection of very low circulating levels of cTn with a higher 
precision [35-37]. The increased assay sensitivity is achieved by several 
modifications of the existing immunoassays. For instance, the hs-cTnT assay 
(Roche Diagnostics) requires a larger sample volume than the previous assay 
(50 µL instead of 15 µL). Moreover, signal amplification is obtained by the use of 
highly optimized antibody-ruthenium conjugates and interference by heterophilic 
antibodies has been reduced by using a chimeric mouse-human antibody as the 
detector antibody  [34].  
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The introduction of hs-cTn concentrations resulted in an earlier detection of AMI. 
Several large clinical trials have demonstrated that the high-sensitivity assays 
have superior diagnostic performance in patients with suspected acute coronary 
syndromes in comparison to the contemporary assays [38-41]. Improved 
sensitivities have been reported for the hs-cTnT assay of Roche Diagnostics 
(from 83% to 95%) [40] and hs-cTnI assay of Abbott Diagnostics (from 79% to 
82%) [39] (TABLE 1).  Overall, this has enabled the earlier detection of the 
onset of AMI [40-42].  
However, increased analytical sensitivity has come at the cost of decreased 
specificity (TABLE 1) and thus presenting additional diagnostic challenges for 
clinicians. Though cTn elevations signifies damage to the myocardium, cTn is 
not specific for one particular cardiovascular disease, such as AMI. Any 
condition that causes injury to the cardiomyocytes can result into increases in 
circulating hs-cTn concentrations, for example heart failure and myocarditis [44]. 
Furthermore, hs-cTn also accumulates in patients with chronic kidney disease 
[45], including end-stage renal disease (ESRD) [46, 47] but are usually stable 
and modest in such cases. The exact mechanisms that lead to these elevated 
cTn concentrations are not yet known, but it seems likely that a decrease in 
renal clearance contributes to this. In principle, cTnT and cTnI (intact or 
fragments) are small enough to be filtered by the kidneys [48]. Nevertheless, 
also in these patients, baseline hs-cTn concentrations remain strongly 
associated with increased cardiovascular risk and mortality [49-51].  
Acute processes typically manifest with a rising and/or falling pattern, whereas 
chronic diseases generally do not. Subsequently, serial hs-cTn testing has 
demonstrated promising results in distinguishing acute from chronic disease 
[39, 52, 53] by assessing absolute or relative changes, though absolute 
changes appear to be superior especially in the lower measuring range [54, 55]. 
Many different absolute (5-7 ng/L) and relative (20-50%) deltas have been 
reported, and increasingly earlier time-frames for monitoring is currently 
suggested (3-6 versus 1-2 hours) [54, 56]. 
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Low levels of hs-cTn concentrations as a risk stratifying tool 
Hs-cTn assays are capable of measuring hs-cTn concentrations in most healthy 
reference subjects [35-37]. Several large clinical trials have demonstrated that 
low hs-cTnT [57-60] and hs-cTnI [61-64] concentrations, even below the 
diagnostic cut-off, are associated with the presence and severity of a wide range 
of cardiac abnormalities, including CAD [65, 66], cardiac morphology and 
function [67, 68]. Also, the association of hs-cTn concentrations with a higher 
risk on developing cardiovascular events and all-cause mortality has been well-
established in numerous populations [57-64, 69], from general cohorts [68] to 
stable chest pain patients [62]. Even when adjusted for traditional 
cardiovascular risk factors such as smoking, diabetes mellitus and 
hypercholesterolemia, hs-cTn concentrations remain important risk predictors. 
However, whether all detectable hs-cTn concentrations represents myocardial 
necrosis, remains to be elucidated. As such, other mechanisms have been 
proposed for these low levels of circulating cTn [70], for instance physiological 
renewal or remodelling of the heart [71], and cTn leakage from reversibly 
damaged cardiomyocytes during transient ischemia [72, 73].  
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Thesis outline 
With the introduction of more sensitive cardiac troponin assays in the clinic, 
clinicians are often challenged when interpreting troponin values, especially in 
the lower measuring range. This thesis will shed light on important questions 
concerning the high-sensitivity assays and offers insight in the underlying 
reasons for hs-cTn elevations.  
An overview of 99
th
 percentile upper reference limits and underlying reference 
populations is given in chapter two. In this chapter the challenges of defining a 
"cardio-healthy" reference population are discussed.  
The interpretation of baseline hs-cTn values in the individual patient is 
complicated not only by cardiac disease but also renal dysfunction. As of yet it is 
unknown to what extent renal function contributes to higher cardiac troponin 
concentrations in patients with chest discomfort, in whom circulating hs-cTnT 
concentrations are mainly attributed to the presence and severity of 
atherosclerotic plaques or echocardiographic abnormalities. In-depth 
understanding of the relative contribution of renal function, next to 
cardiovascular disease, is examined in chapter three. In line with this, chapter 
four describes the effect of heart failure and renal dysfunction on hs-cTn 
concentrations, measured in an aged population (>65 years) of nursing home 
residents.   
ESRD patients often exhibit elevated cTn levels that are more stable over time. 
To date, it remains unclear how dialysis affects cTn results, as both intradialytic 
increases and decreases have been reported. In chapter five hs-cTn 
concentrations before and after different modalities of hemodialysis are 
therefore investigated.  
There is evidence that cTn proteins can be subjected to posttranslational 
modifications, such as degradation. Which circulating cTnT forms are detected 
by the clinical assay in the blood of AMI and ESRD patients are investigated in 
chapter six and chapter seven, respectively.  
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Abstract  
Cardiac troponins (cTn) are the preferred markers for the diagnosis of acute 
myocardial infarction (AMI). The guidelines recommend the use of the 99
th
 
percentile upper reference concentration of a healthy population as the 
diagnostic cutoff for AMI. However, a broad range of upper reference limits is 
still employed, complicating the diagnosis of AMI.  
This overview is meant to assist laboratory specialists to define an appropriate 
cutoff value for the diagnosis of AMI. Therefore we provide an overview of the 
analytical performance and upper reference limits of seven (high-)sensitivity cTn 
assays: Roche high-sensitivity cTnT and ADVIA Centaur, Stratus CS, 
Dimension Vista, Vitros ECi, Access and Architect cTnI assays.  
It is shown that none of the reference populations completely met the 
guidelines, including those in package inserts. 40% of the studies collected less 
than the advised minimum of 300 subjects. Many studies (50%) did not report 
their inclusion criteria, while lower 99
th
 percentile limits were observed when 
more stringent selection criteria were applied. Higher troponin cutoffs were 
found in men and elderly subjects, suggesting gender- and age-specific cutoffs 
would be considered. Therefore, there is still need for a large, rigorously 
screened reference population to more accurately establish cTn upper 
reference limits. 
 
 
 
 
 
 
 
 
 
List of Abbreviations: cTn, cardiac troponin; ACS, acute coronary syndrome; NACB, National Academy for 
Clinical Biochemistry; ESC, European Society of Cardiology; ACC, American College of Cardiology; AMI, acute 
myocardial infarction; cTnT, cardiac troponin T; cTnI, cardiac troponin I; CV, coefficient of variation; hs-cTnT, 
high-sensitivity cTnT; LoB, limit of blank; LoD, limit of detection; RCV, reference change value; CVA, analytical 
coefficient of variation; CVI, within-subject coefficient of variation; II, index of individuality; CVG, between-
subject coefficient of variation; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; 
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Introduction 
Cardiac troponins (cTn) were generally recommended as the biochemical gold 
standard for the investigation of patients with acute coronary syndrome (ACS) in 
1999 by the National Academy of Clinical Biochemistry (NACB) [1], and in 2000 
by the European Society of Cardiology and the American College of Cardiology 
(ESC/ACC) [2]. Both clinical [3] and analytical aspects [4, 5] of these guidelines 
were revised in 2007, in order to establish a more universal definition of acute 
myocardial infarction (AMI). According to these guidelines a rise and/or fall of 
cardiac troponin T (cTnT) or I (cTnI) with at least one value above the 99th 
percentile of a healthy reference population is the hallmark of myocardial 
damage. To complete the diagnosis, cTn changes must be accompanied with at 
least one of the following clinical factors: the presence of ischemic symptoms, 
electrocardiographic (ECG) alterations (for example ST-T changes, left bundle 
branch block or development of pathological Q waves), or imaging evidence of 
either new loss of viable myocardium or new regional wall motion abnormality 
[3, 6]. Importantly, the guidelines recommend a total imprecision (CV) of 10% at 
the 99th percentile reference limit [5]. In a recent overview, Apple classified the 
available assays [7] as “not acceptable” (CV >20%), “clinically usable” (CV 10-
20%) or “guideline acceptable” (CV ≤10%) [8]. In addition, assays were 
categorized into 4 levels depending on whether <50% (level 1), 50-75% (level 
2), 75-95% (level 3) or >95% (level 4) of reference concentrations had 
detectable cTn concentrations below the 99th percentile. Only nine out of 
twenty-two assays were labeled “guideline acceptable” and nine were defined 
as “clinically usable” [8]. However, as recently pointed out, misclassification of 
patients when using CVs between 10% and 20% at the 99th percentile is 
considered to be insignificant [9].  
Despite the introduction of guideline acceptable assays and the 
recommendation to use the 99th percentile value of a reference population as 
cutoff for AMI, a broad range of cutoff concentrations are in use, complicating 
the diagnosis of AMI for clinicians. A major cause of this heterogeneity is lack of 
assay harmonization and non-standardized selection of healthy reference 
populations [10-12]. This issue will become even more prominent with the 
ongoing development of increasingly sensitive assays that detect measurable 
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cTn levels in almost everybody. Noteworthy, recent data indicate that even low 
levels of cTn can predict major adverse cardiac events, pointing out the 
importance of reliable diagnostic cutoffs [13, 14].  
Most laboratories do not have the resources to determine their own 99th 
percentile cutoff. For appropriate statistical determination of the 99th percentile 
cutoff a theoretical minimum of 120 reference subjects has been proposed [15]. 
In order to reliably assess the 99th percentile with an uncertainty <5%, a sample 
size of 300 subjects is required [5, 6]. Furthermore, the distribution of gender 
and age in the reference population should resemble those in a typical group of 
AMI patients, and should ideally have negative exercise stress tests and normal 
cardiac function as assessed by non-invasive imaging. The CARMAGUE study 
pointed out that ± 50% of the laboratories employ cutoff values from the 
package insert, 15% adopt values from peer-reviewed studies [16], and 
sometimes arbitrarily chosen values are used. A structured overview of all 
studies may be a helpful tool that facilitates the diagnostic process and assists 
laboratories to define appropriate cutoff values. 
In the present review, we provide an extensive summary of seven cTn assays, 
frequently used in clinical practice, that can measure the 99th percentile cutoff 
with a high precision, including five “guideline acceptable” assays: 1) high 
sensitivity cTnT (hs-cTnT, Roche Diagnostics), 2) ADVIA Centaur TnI-Ultra 
(Siemens Healthcare Diagnostics), 3) Stratus CS Acute Care cTnI (Siemens 
Healthcare Diagnostics), 4) Dimension Vista cTnI (Siemens Healthcare 
Diagnostics) and 5) Vitros ECi cTnI ES (Ortho Clinical Diagnostics) assays. We 
also included two “clinically usable” assays to complete the overview: 6) Access 
AccuTnI (Beckman Coulter) and 7) Architect cTnI assay (Abbott Diagnostics). 
Point-of-care tests and research assays were excluded. Between October 2010 
and October 2011, we searched the MEDLINE electronic database for 
publications in English, using the key words “troponin”, “troponin assay”, and 
“99th percentile”. We paid special attention to analytical assay characteristics 
and the 99th percentile cutoffs. We also discuss selection criteria of the 
reference population, gender/age specific differences in cTn concentrations, 
and biological variation within or between subjects. These are increasingly 
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prominent subjects of debate since the introduction of the high sensitivity 
assays. 
Hs-cTnT Assay, Roche Diagnostics 
The analytical evaluation of the assay established by the manufacturer (Roche 
Diagnostics, Mannheim, Germany) described a limit of blank (LoB) of 3 ng/L and 
limit of detection (LoD) of 5 ng/L. As depicted in TABLE 1A, other studies 
reported LoDs that ranged from 1 to 5 ng/L [17-21]. According to the package 
insert a 10% CV was measured at 13 ng/L (version 2010).  Most authors found 
the same value or even lower 10% CV cutoffs [18, 22-26]. Only one study 
reports a noticeable higher 10% CV of 18.5 ng/L [27]. These discrepancies in 
LoB, LoD, and 10% CV can be the result of using various methods of estimation 
[11].  
The reference populations were selected by either health questionnaires [21], 
laboratory tests [17, 22], or both approaches in combination with 
echocardiography [25, 27]. In most studies inclusion criteria were not described 
[18-20, 23, 24]. The recommended inclusion of at least 120 cardio-healthy 
reference subjects, required for reliable estimation of the 99
th
 percentile, was 
met in most studies, except in Koerbin et al and Vasatova et al using 104 and 73 
subjects, respectively [19, 25].  
The 99
th
 percentile concentration according to the package insert was 14 ng/L 
and calculated from 533 healthy subjects. This value was reproduced in four 
independent studies [18, 20, 21, 24]. However, in literature, slightly lower 99
th
 
percentile limits (± 12 ng/L) were described in a large reference cohort (n=1061) 
of healthy subjects using EDTA plasma samples [17] or a small population of 
104 subjects, broadly screened by means of questionnaires to exclude possible 
risk factors, presence of cardiac diseases and cardiovascular medications, 
followed by stress echocardiography and routine chemistry tests [25]. In our lab, 
a cutoff of 16 ng/L was found [22] and similar 99
th
 percentile cutoffs were also 
reported by others, using smaller reference populations [26], comprised of 66% 
males [19]. 
Gender related differences in cTnT levels have been documented using the hs-
cTnT assay [18, 21, 22, 24, 25, 27]. All studies except one [27] reported higher 
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cTnT concentrations in males (P<0.01). From the reported concentrations in 
TABLE 1, we calculated a mean 99
th
 percentile cutoff of 15.0 ng/L for males and 
9.6 ng/L for females [21, 22, 24, 25]. It has been suggested that this could be 
due to gender specific differences in the pathophysiology of ACS [21], or 
variations in mean heart sizes between men and women [22]. Several studies 
indicated higher cTnT levels in elderly [18, 22, 25]. Significantly higher cTnT 
levels were found in people over 60 years, compared to younger subjects, both 
in the male and female cohort (P<0.01) [25]. These findings provide an 
independent replication of a previous report [28].  
Taken together, the 99
th
 percentile cutoff varied between 12 to 17 ng/L. 
Moreover, in all studies but one, the imprecision was ≤ 10%. 
Architect cTnI assay (Abbott Diagnostics) 
The lowest cTn concentration that can be measured with an analytical 
imprecision of 10% was reported to be 32 ng/L by the manufacturer (Abbott 
Diagnostics, Abbott Park, IL, USA) and others [22, 29-31] (TABLE 1B). In the 
remaining publications, the 10% CV values were indicated to be higher, ranging 
from 40 ng/L to 75 ng/L [32-35] .  
The screening methods for the reference populations were primarily not 
specified [30-32, 36]. For this assay, only three reference populations were 
screened by means of medical history check, ECG and blood laboratory tests 
[29, 34, 35]. One study  included less than the advised minimum of 300 subjects 
[34]. The reference population, used by the manufacturer, consisted of 224 
apparently healthy subjects.  
For the 99
th
 percentiles cutoff a concentration of 28 ng/L was found by the 
manufacturer and many others report similar results [30, 31, 33, 36]. Six 
independent studies, report cutoffs lower than 20 ng/L [22, 32, 34-36]. Only one 
study reported noticeably higher 99
th
 percentile cutoffs in a reference population 
of 442 subjects, screened by means of medical history check, ECG and routine 
blood analysis [29]. 
Age and gender related differences in 99
th
 percentile cutoffs were not 
statistically significant among these studies.  
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In summary, upper reference limits varied between 13 and 30 ng/L, while for the 
10% CV cutoff, values between 30 and 76 ng/L were reported.  
Access AccuTnI assay (Beckman Coulter) 
Evaluation of the analytical sensitivity by the manufacturer (Beckman Coulter, 
Woerden, the Netherlands) indicated a LoD of 4 ng/L according to the package 
insert (version 2006). 60 ng/L is the lowest cTnI concentration which can be 
measured with a 10% CV. Various studies reported similar [37-39] or somewhat 
higher values: 104 ng/L [34]; 101 [35] and 75 [40]. 20% CVs were obtained at 43 
ng/L, 34 ng/L and 15 ng/L respectively (TABLE 1C). Recently, the AccuTnI 
assay was optimized resulting in a lower 10% CV value of 14 ng/L [41, 42]. 
As described previously, the reference populations consisted mostly of 
apparently healthy subjects, with no details on how the subjects were screened 
[36, 38, 39, 43-45]. In the various studies, health questionnaires were applied 
either alone [35, 46], or in combination with ECG and routine blood analysis [29, 
34, 40, 42, 47]. Eggers et al clearly showed that a lower cutoff was found when 
screening for cardiovascular diseases (28 ng/L) in comparison to the 
unscreened reference population (44 ng/L) [41]. 
Similar 99
th
 percentile cutoff as indicated by the package insert (40 ng/L) were 
mostly described using a wide variety of reference populations [29, 34, 36, 37, 
39, 44, 45, 47]. Lower cutoffs were found when less than 300 subjects were 
included [38, 43, 48] or  in a relatively young population [35]. On the other hand, 
higher 99
th
 percentile concentrations (60-80 ng/L) were also measured [40, 42]. 
A sample matrix effect was observed between serum and plasma [40], although 
others opposed this finding [29, 47, 48].  
Gender-related differences in the 99
th
 percentile cutoffs were reported to be 
statistically significant in three studies [41, 44, 46]. Ethnicity was also reported 
to affect the 99
th
 percentile cutoff [46], although later on this observation was 
contradicted in another study [44].  
Conclusion. Wide variations in 10% CV values and 99
th
 cutoffs are observed 
ranging from 14-104 ng/L and 13-80 ng/L respectively. In some but not all 
studies the 99
th
 percentile was  measured with a CV < 10%, indicating guideline 
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acceptance. However, many reported cutoffs were not in agreement with the 
manufacturer’s statements. 
ADVIA Centaur TnI-Ultra Assay, Siemens Healthcare Diagnostics 
Analytical sensitivity. Four studies with the new generation ADVIA centaur 
reported a LoD of 6 ng/L [35, 49-51], and one study found a slightly higher LoD 
of 8.5 ng/L [52]. The package insert (Siemens Healthcare Diagnostics, Frimley, 
Camberley, UK, version 2009) stated that the LoD of the ADVIA Centaur TnI-
Ultra assay is 6 ng/L and 30 ng/L is the minimum concentration that could be 
measured with an analytical imprecision of <10%. This value was reproduced in 
four studies [35, 42, 51, 53], but higher 10% CV cutoffs ranging from 45 ng/L to 
67 ng/L [34, 49, 50, 52, 54] were also reported (TABLE 1D). 
A cardio-healthy reference population was selected by laboratory tests [49, 54], 
sometimes  in combination with echocardiography [34, 42, 50, 55]. Three 
studies excluded cardiac diseases and their possible risk factors by means of 
medical history examinations and/or health questionnaires [35, 52, 53]. The 
majority of studies included >300 subjects. Only two studies included less than 
the recommended 300 subjects [34, 52] from which one study did not meet the 
minimum inclusion of 120 subjects [34]. 
The 99
th
 percentile cutoff measured by the manufacturer is 40 ng/L, for both 
serum and plasma samples. Similar values were found in two studies [50, 51] 
but 1.5 to 2 fold higher 99
th
 percentile concentrations have also been reported 
for lithium heparin plasma and serum samples [42, 49, 52-55]. Venge et al 
attributed their higher 99
th
 percentile cutoff (80 ng/L) to different inclusion criteria 
of the reference population, or the use of samples that had been frozen for a 
substantial length of time [42]. It should be noted that an older population was 
used in this study. A majority of the subjects were male and three outliers were 
excluded with no reported reason. Tate et al included only 108 subjects in the 
reference population, rigorously screened for cardiovascular risk factors, cardiac 
diseases, cardiovascular medications, stress echocardiography, blood and urine 
routine tests and heterophilic antibodies against cTn, which could explain the 
relatively low 99
th
 percentile concentration of 21 ng/L found both in plasma and 
serum samples [34]. Even lower 99
th
 percentile cutoffs (13 ng/L and 18 ng/L for 
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plasma and serum, respectively) were reported in a relatively young reference 
population with a mean age of 30 years [35].  
Gender dependent differences were also reported, with significantly higher cTnI 
concentrations in men than in women (P<0.05)[35, 49, 54, 55]. Statistically 
significant correlations between age and cTnI concentrations were reported 
(R=0.268; P<0.0001) [49, 54], and in line with this observation older subjects 
had higher cTnI levels than the younger subjects (P≤0.0002) [42, 55]. No 
significant differences in 99
th
 percentile cutoffs were found among multi-ethnical 
Asian populations [53].  
In conclusion, 10% CV and 99
th
 percentile cutoffs ranged between 30 – 67 ng/L 
and 13 – 87 ng/L, respectively. Most, but not all studies [34, 35, 50] concluded 
that the ADVIA Centaur TnI-Ultra Assay is guideline acceptable. 
Stratus CS Acute Care cTnI Assay, Siemens Healthcare Diagnostics 
The analytical evaluation of the assay established by the manufacturer 
(Siemens Healthcare Diagnostics) yielded a LoB of 30 ng/L and a LoD of 60 
ng/L, while other studies reported LoDs ranging from 10 to 20 ng/L [56-59]. 
According to the package insert 60 ng/L is the minimum concentration that can 
be measured with an analytical imprecision of <10% (version 2001). In literature 
similar results were found [57-59] (TABLE 1E). 
The reference population was not specified in three studies, including the 
package insert, [57, 58]. One study screened for history of cardiac disease, 
hematochemical alterations and hyperpyrexia [59]. One study performed a 
history check, ECG, treadmill tests, stress echocardiography or angiogram [56]. 
Three studies, including those of the manufacturer, analyzed sample sizes that 
were smaller than the minimum number of 120 subjects [57, 59]. Only 
Christenson et al included more than the recommended 300 subjects [58].  
The 99
th
 percentile concentration provided by the manufacturer is 70 ng/L. This 
value was reproduced by Christenson [58], but lower cutoff concentrations of 30 
ng/L [59] and 50 ng/L [57] were also reported with an accompanying 10% 
CV/99
th
 percentile ratio of 2.33 and 1.20 respectively. These lower estimations 
may be due to the inclusion of younger subjects, and the small sample size. 
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In conclusion, only one reference population included a sufficiently large sample 
size and reported the assay to be guideline acceptable [58]. More studies are 
however needed for the Stratus CS assay to make valid conclusions. 
Dimension Vista cTnI Assay, Siemens Healthcare Diagnostics 
Analytical validation of the Dimension Vista cTnI assay by the manufacturer 
(Siemens Healthcare Diagnostics) yielded a LoB of 15 ng/L and a total 
imprecision (CV) below 10% at 40 ng/L (version 2008). Only one independent 
study validated the sensitivity of the Dimension Vista cTnI Assay, and reported a 
LoB, LoD and 10% CV cutoff of 11, 15, and 36 ng/L, respectively [60].  
The reference population collected by the manufacturer included 199 people 
with no clear description of the applied screening methods. Arrabola et al 
included 350 individuals (73% male) after examination of the patient’s medical 
history [60] (TABLE 1F).  
The 99
th
 percentile cutoff calculated by the manufacturer is 45 ng/L. Arrabola et 
al reported a lower cutoff (22 ng/L), and a 10% CV/99
th
 percentile ratio of 1.64.  
No significant gender and age related differences in cTnI levels are currently 
described for this assay.  However, caution is required in interpretation of the 
limited available evidence [60]. 
In conclusion. Although more studies are required to confirm these results, the 
Dimension Vista cTnI Assay is not guideline acceptable according to the current 
evidence in literature [60]. 
Vitros ECi Troponin I ES Assay, Ortho Clinical Diagnostics 
Analytical validation of the Vitros ECi cTnI ES assay by the manufacturer (Ortho 
Clinical Diagnostics, Buckinghamshire, UK) yielded a LoB of 7 ng/L and a LoD 
of 12 ng/L. The package insert (version 3.0) states that the lowest concentration 
measurable with an imprecision (CV) less than 10% is 34 ng/L. Tate and 
colleagues replicated this result [34], but other studies reported 10% CV cutoffs 
of 40 ng/L [61] and 93 ng/L  [35] (TABLE 1G). 
The reference populations used by Tate et al and La’ulu et al have already been 
described above (section on the TnI-Ultra assay) [34, 35]. Apple and colleagues 
recruited serum samples of 2992 healthy subjects, without additional 
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specification, as well as lithium heparin plasma samples from 2000 healthy 
subjects, aged between 18-66 years and of which 75% were male [36]. 
The 99
th
 percentile cutoff calculated by the manufacturer is 34 ng/L, which 
corresponds exactly to the 10% CV cutoff value. Apple et al calculated the 99
th
 
percentile in two independent reference populations [36]. In one cohort with 
serum samples they replicated the cutoff value from the manufacturer, in the 
second reference population with heparin plasma samples a 99
th
 percentile 
concentration of 31 ng/L was reported [36]. Other studies by Tate et al, and 
La’ulu et al calculated much lower 99
th
 percentile concentrations in populations 
that were extensively screened [34], or comprised relatively young subjects [35]. 
However, the concentrations reported at an imprecision of 10% CV were 
markedly higher than the 99
th
 percentile concentration in these studies.  
In conclusion, various 10% CV values and 99
th
 percentile cutoffs were 
observed. All studies but one [36] reported a 10% CV/99
th
 percentile ratio >1. 
Therefore, it remains controversial whether this assay can measure the 99
th
 
percentile with a precision of 10%, as quoted by the package insert.  
How were reference populations established? A summary  
Despite all efforts, heterogeneity in the functional sensitivity and 99
th
 percentile 
cutoffs is clearly demonstrated in TABLE 1. The reported upper reference limits 
deviated from the cutoffs provided by the manufacturer, due to variations in 
sample size, health condition, age, gender and ethnicity. In addition, (pre-) 
analytical factors may have contributed to cutoff discrepancies e.g. serum 
versus plasma samples [11, 62] or the use of different platforms. Variations in 
the determination (e.g. using variable number of days, replicates or different 
platforms) of the functional sensitivity, could explain the range of 10% or 20% 
CV cutoffs that have been reported in literature. 
The broad variation is apparent from the reviewed studies (66 studies; 53 
publications) with sample sizes from <100 to >10,000 subjects. Most studies 
(40%) included less than the advised minimum of 300 subjects and 15% of the 
studies collected even less than 120 subjects. Notice that with a sample size of 
120, 300 or 1000 subjects the 99
th
 percentile cutoff can be strongly affected by 
respectively only 1, 3 or 10 subjects.   
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Another concern is the variation in inclusion criteria among studies. The majority 
of studies (50%) reported no inclusion criteria, suggesting that no extensive 
screening was performed. In 26% of the studies, the reference populations were 
screened by means of medical history questionnaires and/or laboratory tests. In 
24% of the cases it was combined with ECG or cardiac imaging techniques 
such as stress echocardiography or angiography. Herein, no reference 
population met the selection criteria described in the guidelines [6] However, in 
four studies the guidelines were nearly accomplished, reporting a reference 
population comprised of more than 300 individuals and screened by means of 
non-invasive imaging [29, 42, 50, 55]. It must be noted that in two of these 
studies the same reference population was used (SWISCH study) [29, 42]  
Importantly, studies that most extensively screened their reference population, 
reported lower 99
th
 percentile cutoff concentrations [25, 29, 34, 41, 47, 50]. 
Evidently, in smaller reference populations more stringent screening methods 
can be performed, improving the composition of the reference population [25, 
27, 34, 59]. This is counterbalanced by the fact that a small sample size makes 
the 99
th
 percentile cutoff more prone to outliers.  
Ideally, the distribution of gender and age in the reference population resembles 
those of a typical group of AMI patients [6, 15]. However, age distribution in the 
reference populations varied widely among studies. A majority chose a broad 
age distribution (25-75 years), but some reference populations were composed 
of merely younger [35, 60] or older subjects [42, 50]. Only two publications use 
a group of reference individuals in the same age category as AMI patients (>45 
years) [42, 50]. The 99
th
 percentile cutoff concentration had a tendency to 
increase with age [22, 25, 42, 50, 54]. This supports recent ROC analysis from 
Reiter et al who reported that optimal diagnosis for AMI was achieved at higher 
cutoff concentrations in elderly (54 ng/L) as compared to younger subjects (17 
ng/L) [63]. Moreover, gender specific differences in the 99
th
 percentile cutoff 
concentration are frequently reported. The cTnT and cTnI assays measured 
respectively 1.7- and 1.2-fold higher cTn levels in men than women [21, 22, 24, 
25, 34, 49, 54, 55]. Also ethnicity was reported to affect the 99
th
 percentile cutoff 
[46], although others contradict this finding [19, 44]. Taken together, these 
findings add to the existing body of evidence that gender and age influence cTn 
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levels [64]. Future research should reveal whether gender- and age-specific 
cutoff values can improve diagnostic or prognostic performance. 
Current status on biological variation  
The NACB recommends using the rising and/or falling pattern of cardiac 
troponin obtained by serial measurements. They propose a ≥20% change in 
cTn concentration to be suggestive of AMI [4]. A twenty percent difference 
exceeds 3 analytical standard deviations, but it neglects the contribution of the 
biological variation to cardiac troponin levels when measuring in the lower range 
[65]. A better approach may be the reference change value (RCV). The RCV is 
established in healthy individuals and calculated as follows: 
222 IA CVCVzRCV  ; where z is the standard deviation for a 
certain probability [65]. , and CVA and CVI represent the analytical and biological 
variation respectively. When troponin concentrations are measured at two time 
points, and the subtraction of both values exceeds a critical value, defined by 
the RCV, the change is considered significant. Using this approach, Wu et al 
established the log-normal RCV for a hs-cTnI assay (Erenna Immunoassays, 
Singulex). They concluded that an increase of 48% or a decrease of 32% over a 
four hour period (short term), and +81% or -32% change over an eight week 
period (long term) is required [66]. Log-normal RCVs have also been calculated 
for cTnT using the hs-cTnT assay [20]. For short term changes, the cTnT 
concentration must rise 85% to exceed the critical difference, whereas for long 
term changes a >3 fold increase is required.  
Another way to express the biological variation is the index of individuality (II). 
The II can be calculated by the simplified formula: CVI/CVG (within subject 
variation/between subject variation) [67]. By definition, reference intervals are 
more useful for biomarkers with a high II (>1.4) than for markers with a low II 
(<0.6) [68]. For cTnI, the CVI is smaller than the CVG, both for short-term and 
long-term measurements (9.7% versus 57%, and 14% versus 63% respectively) 
[66]. This results in a short-term II of 0.21 and a long term II of 0.39. When the II 
is low as for cTnI, it has been proposed to subdivide the reference population 
into more homogenous reference cohorts, which will improve the  II and the 
usefulness of the marker in clinical practice [67]. The short- and long-term II for 
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cTnT were higher, 0.84 and 1.4, respectively (CVI, 48% and 94%; CVG, 86% and 
94% for short- and long-term, respectively) [20]. Overall, cTnT seems to be 
more useful than cTnI, but with only one cTnI and one cTnT study published, 
more studies are required for a more decisive conclusion. 
Conclusion and future perspective 
In general, large heterogeneity in 99
th
 percentile cutoff values of cTn 
complicates the diagnosis of myocardial infarction. Major causes are lack of 
cardiac troponin assay harmonization, and non-standardized selection of 
individuals in healthy reference populations. We reviewed the literature on 
reference populations for seven (high-)sensitivity assays used in clinical practice 
and found that the upper reference limits deviated from the package inserts for 
all assays, although this was less apparent for the hs-cTnT assay. 
As for now, the best way to establish a reference population is still debatable. 
From all reviewed literature, no reference populations were collected according 
to the guidelines [5, 6] although three nearly met the required standards [29, 42, 
50, 55]. A total of 40% of the studies collected less than the advised minimum of 
300 subjects for reliable estimation of the 99
th
 percentile cutoff and 50% of the 
studies did not report their inclusion criteria. Moreover, there is important 
suggestive evidence that substantially lower cutoff values were calculated in 
studies that applied the most stringent selection criteria to their reference group. 
The available literature supports the concept that age and gender are important 
determinants of cardiac cTn levels. Men have on average 1.7- and 1.2-fold 
higher cTn levels, measured with the cTnT and cTnI assays respectively, and 
the 99
th
 percentile cutoff concentration increases with age [22, 25, 42, 50, 54].  
There is thus need for a large and highly screened population of cardio-healthy 
subjects that are preferably gender-and age-matched for AMI patients. As 
proposed by the IFCC, multicentre studies can be the answer to heterogeneity 
in reference populations: a large number of reference subjects, collected at 
national scale that can be adopted by clinical laboratories to determine the 99
th
 
percentile cutoff values [69]. Alternatively, the optimal cutoff value can be 
defined by ROC analyses [63], reference change values, or the 97.5
th
 percentile 
can be chosen as diagnostic cutoff [1], which would be less sensitive to outliers.  
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Further research should reveal whether more stringent selection criteria and 
gender/age-specific cutoffs can optimize the use of cTn for diagnostic and 
prognostic purposes, or whether alternative approaches such as the use of 
reference change values have added value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 1. Analytical characteristics, 99th percentile cutoffs and baseline characteristics of the reference study 
populations of seven commercially available cTn assays, classified as either guideline acceptable or clinically 
usable [8]* (next page) 
 
 
* BMI, indicates body mass index; CVD, cardiovascular disease; Li, Lithium; NT-proBNP, N-terminus pro- Brain 
Natriuretic Peptide; n.s., not significant; -,  not reported; a, Intra-assay imprecision of 5% at 10 ng/L and 1% at 
100 ng/L; b, CV at 13.5 ng/L <10%; c, Mean ± SD; d , Significant differences in cTnT concentrations between the 
same decades of age in males and females; e, 10% CV cutoffs were all <99th percentile, except for one; f, 
Mean; g, Mean (95% Confidence Interval); h, as quoted by the manufacturer i, median age; j , Intra-assay 
imprecision of 9.6% at 11 ng/L; k, 42% Malays, 30% Chinese, 27% Indians; l, Mean of ADVIA Centaur CP and 
ADVIA Centaur platform; m ,20% CV cutoff concentration; n, Mean ± 2 SD 
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Abstract 
Background 
The extent of renal influence on hs-cTn concentrations is still unknown in 
patients suspected for coronary artery disease (CAD) and is necessary for 
appropriate interpretation of low-level hs-cTn concentrations. We therefore 
simultaneously investigated the renal and cardiac contribution to hs-cTn 
concentrations in chest discomfort patients from the cardiology outpatient 
department. 
Methods 
A cross-sectional analysis was performed in 1864 patients with symptoms of 
chest discomfort who underwent cardiac computed tomographic angiography 
(CCTA). Serum samples were analyzed using hs-cTnT and hs-cTnI assays. 
Renal function was measured by the estimated glomerular filtration rate (eGFR), 
established from serum creatinine and cystatin C. On follow-up, the incidence of 
cardiovascular events was assessed. 
Results 
Median hs-cTnT and hs-cTnI concentrations were 7.2(5.8-9.2)ng/L and (2.6(1.8-
4.1) ng/L, respectively. Both hs-cTn measurements were more strongly 
associated with eGFR (hs-cTnT:stβ:-0.289; hs-cTnI:stβ:-0.222) than with 
cardiac imaging parameters, such as coronary calcium score (hs-
cTnT:stβ:0.078; hs-cTnI:stβ:0.092), CCTA plaque severity score (hs-
cTnT:stβ:0.074; hs-cTnI:stβ:0.072) and left ventricular mass (hs-cTnT:stβ:0.139 
;hs-cTnI:stβ:0.234) (all p≤0.01 and after adjustment for traditional risk factors). 
Moreover, the association between eGFR and hs-cTn remained equally strong 
among patients with no (hs-cTnT:stβeGFR:-0.295; hs-cTnI:stβeGFR:-0.228), 
mild (hs-cTnT:stβeGFR:-0.290; hs-cTnI:stβeGFR:-0.176) and moderate-to-
severe CAD (hs-cTnT:stβeGFR:-0.293; hs-cTnI:stβeGFR:-0.249) (all p<0.001). 
Both hs-cTnT and hs-cTnI remain independent prognostic markers for 
cardiovascular events, irrespective of renal function and CAD.  
Conclusion  
In patients with chest discomfort, we identified decreases in renal function and 
the extent of CAD as two separate contributors of troponin accumulation. 
Awareness of these renal influences is therefore warranted when interpreting 
hs-cTn concentrations. 
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Introduction  
Identifying chest pain patients at risk for cardiovascular events remains an 
ongoing challenge [1]. A promising and cost-effective way to identify those 
“vulnerable” patients is the use of cardiac troponins [2, 3]. Because of their 
unique cardiospecificity, cardiac troponins are considered the preferred 
biochemical markers to detect myocardial injury and to diagnose acute 
myocardial infarction (AMI) in particular [4]. Since the introduction of high-
sensitivity cardiac troponin (hs-cTn) assays, more accurate detection of low 
levels of circulating cardiac troponins became feasible [5]. The use of hs-cTn 
concentrations significantly improved the diagnostic performance in patients 
with acute cardiac risk[6]. Moreover, hs-cTn concentrations turned out to have 
an important prognostic value for acute cardiovascular events, even below the 
diagnostic cut-off and beyond traditional cardiovascular risk factors [7-9]. 
Unfortunately, the shift to more sensitive assays is accompanied by a reduction 
in specificity, as circulating hs-cTn levels are elevated in many other conditions 
besides AMI[7, 10]. Renal dysfunction is one of those conditions in which 
elevated cardiac troponin concentrations are commonly detected [11, 12]. 
Recently it was shown in chronic kidney disease (CKD) patients that elevated 
hs-cTn concentrations are indeed associated with reduced renal function [13]. 
Therefore, the interpretation of baseline hs-cTn values in the individual patient is 
complicated not only by cardiac disease [14-16] but also renal dysfunction. As of 
yet it is unknown to what extent renal function contributes to higher cardiac 
troponin concentrations in patients with chest discomfort, in whom circulating 
hs-cTnT concentrations are mainly attributed to the presence and severity of 
atherosclerotic plaques [2, 3] or echocardiographic abnormalities [17-19]. In-
depth understanding of the relative contribution of renal function, in addition to 
cardiac parameters, is of utmost importance for the use of hs-cTn values in 
clinical practice. 
In this study, we therefore evaluate the association of serum hs-cTnT and hs-
cTnI concentrations with renal function (as assessed by the estimated 
glomerular filtration rate (eGFR)), cardiac imaging measures (cardiac computed 
tomographic angiography (CCTA) and echocardiography), and the incidence of 
cardiovascular events in patients who visited the cardiology outpatient 
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department with symptoms of chest discomfort. Particularly, the renal and 
cardiac contribution to hs-cTnT and hs-cTnI concentrations will be examined 
simultaneously.  
Materials and methods 
Study cohort 
We analyzed a cohort of 1864 consecutive patients who were enrolled in the 
Maastricht Biomarker CT Study (ClinicalTrials.gov, NCT01671930). This cohort 
is comprised of patients presenting with (a)typical chest pain with a low-to-
intermediate pretest probability who were referred for CCTA from the cardiology 
outpatient department for the evaluation of coronary artery disease (CAD), in 
accordance with the current guidelines[1]. Included were patients of whom 
serum was collected.  Excluded were patients with previous history ACS and 
patients on dialysis (due to application of contrast fluids). Additional 
specifications of this population have previously been published [2, 20]. This 
study was conducted according to the principles of the Declaration of Helsinki 
and approved by the local ethics committee. Written informed consent was 
obtained from all patients.  
Biochemical analysis 
Serum samples were collected immediately before CCTA, processed within 2 
hours and directly stored at -80 °C until analysis. Total cholesterol, triglycerides, 
high-density and low-density lipoprotein concentrations were measured as 
previously described [2]. Serum creatinine, cystatin C and cTnT concentrations 
were measured on the Cobas 6000 analyzer (Roche Diagnostics) in a fresh 
aliquot. Creatinine concentrations were assessed using the enzymatic method 
(Roche). Cystatin C was measured using a new particle-enhanced turbidimetric 
assay (Gentian AS), that was standardized against the certified ERM-
DA471/IFCC cystatin C reference material [21]. The glomerular filtration rate 
was estimated using the Chronic Kidney Disease Epidemiology Collaboration 
equations[22] using serum creatinine and cystatin C concentrations. cTnT 
concentrations were determined using the high-sensitivity cTnT assay (Roche; 
lotnumber 167650), with a 99
th
 percentile upper reference limit of 14 ng/L and a 
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10% coefficient of variation cut-off at 13 ng/L. Gender-specific cutoffs were 
reported at 14.5 ng/L and 10 ng/L for males and females, respectively [5]. cTnI 
measurements were performed on the ARCHITECT i2000SR platform using the 
precommercial ARCHITECT STAT high-sensitivity troponin I (hs-cTnI) assay 
(Abbott Laboratories). According to the manufacturer, a 10% CV was reached at 
4.7 ng/L and the 99
th
 percentile cut-off concentration at 26.2 ng/L for the overall 
population. Gender-specific cut-offs at 34.2 ng/L and 15.6 ng/L were also 
defined for males and females, respectively.   
Cardiac computed tomographic angiography 
CCTAs were performed from December 2007 through December 2012 and 
analyzed as previously described [20]. In brief, CCTA were analyzed by two 
experts who were blinded from hs-cTn results. The coronary calcium score 
(CCS) was quantified by the Agatston method[23] and luminal plaque severity 
as assessed by CCTA was scored as no, mild (<50% stenosis), moderate (50-
70% stenosis) and severe (>70% stenosis) CAD.  
Echocardiography  
Echocardiography was performed in a subset of 549 patients (31%) within a 
period of 3 months from the CCTA scan by an expert echocardiographist, who 
was blinded for hs-cTn concentrations. Transthoracic images of the left ventricle 
(LV) were acquired to assess morphology, function and mass (Philips IE 33, 
Philips Medical Systems). LV function and -mass were calculated by off-line 
image analysis using Xcelera software package (Philips Medical Systems), 
according to current ESC/AHA guidelines [24]. Left ventricular hypertrophy was 
defined as an LVmass  >95 g/m
2
 in females or LVmass >115 g/m² in males [25].  
Cardiovascular events 
Electronic patient records were monitored for the occurrence of cardiovascular 
events by two reviewers. Survival time was defined as the period from date of 
CCTA to date of the first cardiovascular event or June 2013. The composite 
study endpoints were defined in advance as major adverse cardiovascular 
events, encompassing cardiovascular mortality, acute coronary syndromes 
including AMI and unstable angina requiring hospitalization; and late coronary 
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revascularization (>90 days after CCTA), such as percutaneous coronary 
interventions and coronary artery bypass grafting [26]. No records could be 
retrieved of 175 subjects, therefore 1689 patients (91%) of the total cohort were 
included for follow-up analysis. 
Statistical analysis 
Comparisons of baseline characteristics were performed using the T-test for 
continuous variables with a normal distribution, Mann-Whitney U-test for non-
normal distributed continuous variables and Chi square test for categorical 
variables. Data are presented as proportions, means ± standard deviations, and 
data with a non-normal distribution are given as the median (interquartile range, 
IQR). Pearson R correlation factors were calculated with the natural logarithm 
(Ln) of hs-cTnT and hs-cTnI to normalize their skewed distribution.  
To assess the independent association of renal and cardiovascular parameters 
with hs-cTn concentrations, linear regression analyses were performed with 
either Ln(hs-cTnT) or Ln(hs-cTnI) as the dependent variable. Only the 
cardiovascular risk factors that were significantly associated to higher hs-cTnT 
quartiles (TABLE 1) were entered into the multivariable model. R² was 
calculated to measure the performance of the model, and the R² change to 
address the additive effect of eGFR to the model. Univariable and multivariable 
cox-proportional hazards models were performed to investigate the association 
with cardiovascular events. The discriminative ability of each predictor was 
assessed using the receiver-operating characteristic (ROC) curves.  
Statistical analysis was performed with SPSS 20.0 (SPSS). Two sided p-values 
of <0.05 were considered statistically significant.  
Results 
Distribution and determinants of hs-cTnT and hs-cTnI 
Median (IQR) hs-cTn concentrations in this cohort were 7.2 (5.8-9.2) ng/L for 
hs-cTnT and 2.6 (1.8-4.1) ng/L for hs-cTnI. Of all patients, 6.6% (n=123) were 
above the cutoff of hs-cTnT (14 ng/L) and 2.1% (n=30) above the cutoff of hs-
cTnI (26.2 ng/L). The majority of all patients (72%) had a normal renal function 
(eGFR>90 mL/min/1.73m²) and 98% had an eGFR above 60 mL/min/1.73m². 
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The baseline characteristics are presented in TABLE 1 and illustrate that 
increasing quartiles of hs-cTnT and hs-cTnI were highly associated with 
traditional cardiovascular risk factors such as advancing age, male sex and 
hypertension. The association between Ln(hs-cTnT) and Ln(hs-cTnI) was only 
moderate (Pearson R: 0.635; p<0.001 and cohen к of 0.27; p<0.001; 
SUPPLEMENTAL TABLE 1).  
Independent association of cardiovascular disease and renal function with hs-cTn 
concentrations  
Univariable regression analysis demonstrated that hs-cTn concentrations are 
significantly associated with eGFR (hs-cTnT: R:-0.396; hs-cTnI: R:-0.251; 
SUPPLEMENTAL FIGURE 1), regardless of the algorithm that is used to 
estimate GFR (SUPPLEMENTAL FIGURE 2). Also, both hs-cTnT and hs-cTnI 
concentrations are significantly correlated with CCS (hs-cTnT: R:0.279; hs-cTnI: 
R:0.213) and CCTA plaque severity (hs-cTnT: R:0.307; hs-cTnI, R:0.230) 
(TABLE 2 and SUPPLEMENTAL FIGURE 3, ALL P<0.001).  
As displayed by FIGURE 1, when adding renal and CT parameters as 
explanatory variables for hs-cTn concentrations in a multivariable regression 
model, both eGFR, CCS as CCTA plaque severity were identified as 
independent predictors (TABLE 2, unadjusted multivariable model).  
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FIGURE 1. Median hs-cTnT (A) and hs-cTnI (B) concentrations according to estimated GFR categories and 
coronary calcium score or CCTA plaque severity. AS, agatston score 
 
 
Similar standardized βeGFR (stβeGFR), stβCCS and stβCCTA coefficients were 
observed in the univariable versus unadjusted multivariable models, indicating 
that CT parameters were hardly influenced by the addition of eGFR when 
predicting hs-cTnT or hs-cTnI concentrations (TABLE 2). After adjustment for 
traditional cardiovascular risk factors, eGFR (hs-cTnT: stβ:-0.289; hs-cTnI: stβ:-
0.222; p<0.001), CCS (hs-cTnT:stβ:0.078; hs-cTnI:stβ:0.092; p<0.001) and 
CCTA plaque severity score (hs-cTnT:stβ:0.0.074; hs-cTnI:stβ:0.072; p<0.001) 
remained significantly associated with hs-cTn concentrations (TABLE 2, 
adjusted multivariable model 1 and 2, respectively). Also here, stβeGFR values 
remain unchanged (TABLE 2, adjusted multivariable models 1 and 3).  
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The independent contribution of eGFR to the prediction of hs-cTnT and hs-cTnI 
concentrations was also demonstrated by significant and identical R² changes 
(hs-cTnT: 0.056, hs-cTnI: 0.030; all p<0.001) when adding eGFR either to the 
baseline model or to adjusted multivariable model 2.  
Furthermore, the association of eGFR with hs-cTn concentrations remained 
equally strong when subdividing this cohort into patients with no (hs-
cTnT:stβeGFR:-0.295; hs-cTnI:stβeGFR:-0.228), mild (hs-cTnT:stβeGFR:-0.290; hs-
cTnI:stβeGFR:-0.176) and moderate-to-severe CAD (hs-cTnT:stβeGFR:-0.293;hs-
cTnI: stβeGFR:-0.249) (all p<0.001), confirming the independent influence of 
eGFR on hs-cTn concentrations beyond CAD severity (TABLE 3). This finding 
was visible but less apparent for hs-cTnI than for hs-cTnT. 
Considering the hs-cTnT concentrations above the 99
th
 percentile 
concentrations, we found that 47% were suffering from significant CAD 
(presence of obstructive plaques or CCS > 400) and 53% had decreased renal 
function (eGFR<90mL/min/1.73m²). Moreover, 72% of the patients with elevated 
hs-cTnT concentrations were diagnosed with CAD or had a decreased eGFR 
(SUPPLEMENTAL TABLE 2). For hs-cTnI, this was 43%, 30% and 58%, 
respectively. Similar findings were observed when applying gender-specific 
cutoffs (data not shown). 
Comparable regression analyses were performed including echocardiographic 
parameters as explanatory variables for hs-cTn concentrations. Univariably, hs-
cTnT and hs-cTnI were significantly associated with the echocardiographic 
measures LVEF (hs-cTnT: R:-0.151, p=0.001; hs-cTnI, R:-0.142, p=0.002) and 
LVmass (hs-cTnT: R:0.253; hs-cTnI: R:0.309; p<0.001) (SUPPLEMENTAL 
TABLE 3 and SUPPLEMENTAL FIGURE 3). In line with previous results, 
stβeGFR coefficients were only influenced by the confounding effects of traditional 
cardiovascular risk factors and not by any of the measured CT parameters or 
echocardiographic parameters (SUPPLEMENTAL TABLE 4).   
In total, 30% and 19 % of hs-cTnT and hs-cTnI variation, respectively, could be 
explained by the most important independent predictors: eGFR, CCS, LVmass, 
age and male sex (SUPPLEMENTAL TABLE 4). 
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Algorithm between eGFR and hs-cTn concentrations 
In patients with an eGFR between 120-130 mL/min/1.73m², median hs-cTnT 
and hs-cTnI concentrations were 6.0 ng/L and 2.0 ng/L, respectively (TABLE 4). 
Moreover, when eGFR was halved to 60 mL/min/1.73m², a doubling of both hs-
cTn concentrations was observed (hs-cTnT: 9.9 ng/L; hs-cTnI: 4.1 ng/L). A 
decrease in eGFR of 10 mL/min/1.73m² corresponded in this population to a 
mean relative increase of 9% and 11% or mean absolute increase of 0.8 ng/L 
and 0.4 ng/L in hs-cTnT and  hs-cTnI concentrations, respectively. 
Hs-cTn remain significant and comparable prognostic markers for cardiovascular events 
Over a mean follow-up period of 2.9±1.5 years, 54 cardiovascular events (3.2%) 
were observed, encompassing 33 patients who underwent late 
revascularization, 18 patients that suffered from a non-fatal acute coronary 
syndrome and 3 patients who died due to cardiac disease (decompensatio 
cordis and myocardial infarction) or vascular causes (cerebrovascular attack). 
From all traditional risk factors, only age, gender and smoking were significantly 
different in the event versus non-event group (SUPPLEMENTAL TABLE 5). 
As depicted in FIGURE 2, univariable Cox regression analysis showed that the 
incidence of cardiovascular events was significantly associated with hs-cTnT 
and hs-cTnI. Moreover, both hs-cTnT and hs-cTnI remained highly significant 
predictors for cardiovascular events when adjusted for eGFR and CCS or CCTA 
plaque severity .  
ROC analysis demonstrated no significant difference between hs-cTnT (area-
under-the-curve, AUC (95% confidence intervals): 0.671(0.599-0.742)) and hs-
cTnI (0.649(0.571-0.727)) in the prediction of cardiovascular events (p>0.05, 
data not shown).  
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FIGURE 2. Hazard ratios and 95% confidence intervals (CI) for cardiovascular events as predicted by hs-cTnT 
or hs-cTnI either unadjusted or adjusted to eGFR and the cardiac imaging parameters: coronary calcium 
score (CCS) and CCTA plaque severity score. *, indicates a p-value <0.001 
 
 
Discussion  
The present study provides new insights into the interpretation of hs-cTn 
concentrations in patients with chest discomfort, identifying renal function and 
CAD as independent and strong contributors to circulating hs-cTn 
concentrations. In fact, in this population eGFR exhibited limited confounding 
effects on the association between hs-cTn and cardiac parameters. 
Significant influence of renal function on hs-cTnT and hs-cTnI concentrations  
We found that hs-cTnT and hs-cTnI were strongly correlated with eGFR in 
patients with chest discomfort, in which 98% had a renal function 
>60mL/min/1.73m². In this cohort, a decrease in eGFR of 10 mL/min/1.73m² 
indicated a ±10% increase in hs-cTn concentrations, equivalent to an absolute 
increase of 0.8 ng/L and 0.4 ng/L for hs-cTnT and hs-cTnI, respectively. 
Although these findings need to be validated in other populations, it clearly 
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illustrates that a decreased renal clearance, even within normal boundaries, can 
affect hs-cTn concentrations and questions whether baseline hs-cTn 
concentrations should be reported without the access to an eGFR.  
As observed in moderate-to-severe CKD patients [13], hs-cTnT was more 
strongly correlated with eGFR than hs-cTnI. In addition, the association 
between hs-cTnT concentrations and eGFR were stronger than any known 
association between hs-cTnT and cardiac parameters, such as coronary plaque 
severity [2, 3, 27] or left ventricular structure [16, 18, 28]. Interestingly, this is in 
contrast to hs-cTnI, in which the association with LVmass was greater than with 
eGFR. These findings suggest that hs-cTnT could be more susceptible to 
changes in renal clearance than hs-cTnI. 
Renal and cardiac parameters as two separate contributors to hs-cTn 
Importantly, in a cohort of patients with normal eGFR values, we demonstrate 
for the first time that the extent of CAD and echocardiographic characteristics of 
the left ventricle did not interfere with the magnitude of the association between 
eGFR and hs-cTn concentrations. As a consequence, in patients with a normal 
to a mildly impaired kidney function, decreases in renal function and the extent 
of CAD can be considered as two separate contributors of  hs-cTn 
accumulation. This independent association with renal function might not only 
be valuable for the evaluation of stable chest pain patients [1] but also chronic 
heart failure and acute chest pain patients [4].  
Furthermore, we show that a significant amount of the patients with elevated hs-
cTn concentrations suffered from decreased renal function, besides the 
presence of CAD. These findings can explain the reduced diagnostic 
performance of hs-cTn seen in AMI patients with lower renal function in 
comparison to those with normal renal function [29, 30]. Further research should 
therefore focus on the influence of mild CKD when acquiring the diagnostic hs-
cTn cutoffs as established from reference populations (99
th
 upper reference 
limit).   
The significant association between eGFR and hs-cTn concentrations, 
independent from cardiac pathologies, is in line with the observation that cTnT 
and cTnI are cleared by the kidneys [31, 32]. However, we cannot exclude that a 
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decreased renal function may exert additional myocardial stress that is not 
identified by cardiac imaging, leading to subsequent cardiac troponin release. 
Prognostic importance of hs-cTnT and hs-cTnI besides CCTA and renal function 
In this study, serum hs-cTnT as well as hs-cTnI were significant prognostic 
markers for the development of cardiovascular events, as previously 
demonstrated [8, 9, 28, 33]. Although hs-cTnT concentrations were twice as 
high as hs-cTnI concentrations, we found the overall prognostic performance of 
hs-cTnT and hs-cTnI to be comparable (AUCROC: 0.670 versus 0.650 for hs-
cTnT and hs-cTnI, respectively).  
Hs-cTnT was shown to be a strong prognostic marker for cardiovascular events, 
despite the influence of a decreased renal function [34, 35]. We found that even 
when adjusted to eGFR, both hs-cTn concentrations still hold an important 
prognostic value besides important cardiovascular imaging parameters such as 
CCS and CCTA plaque severity score. In fact, we were able to explain a quarter 
to one third of the variability in hs-cTn concentrations, suggesting that other 
mechanisms could contribute to the overall hs-cTn level as well.  
Study limitations 
A limitation to our survival analysis is that this is a low-risk population and 
consequently a low number of adverse cardiovascular events were observed. 
Also, we cannot rule out that CCTA outcomes were used in the decision to 
perform a CABG and PCI in these patients. However, we corrected for this bias 
by excluding the procedures that were performed within 90 days after CCTA. 
Furthermore, urine samples were not available for the assessment of 
albuminuria.  
 
Conclusion 
In conclusion, we identified in patients with symptoms of chest discomfort that 
renal function has a significant influence on circulating hs-cTnT and hs-cTnI 
concentrations. Moreover, we found that cardiac pathology and decreases in 
renal function are two independent contributors for hs-cTn accumulation. 
Prospective studies must establish whether baseline hs-cTn concentrations 
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should be accompanied by GFR-assessment. Notwithstanding, hs-cTnT and hs-
cTnI remained significant predictors of cardiovascular events, even on top of 
cardiovascular disease and renal function. 
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SUPPLEMENTAL FIGURE 1. Scatterplots of the association of eGFR with Ln (hs-cTnT) (A) and Ln (hs-cTnI) (B).  
 
SUPPLEMENTAL FIGURE 2. Association of hs-cTnT (blue) and hs-cTnI (grey) with GFR estimated by the MDRD 
equation (A) and the CKD EPI equations using serum creatinine (B), serum cystatin C (C) concentrations or 
both (D). *p-value <0.05 in comparison with eGFR 31-60 ml/min/1.73 m2 group. Pearson R correlation 
factors with the natural logarithm of hs-cTnT and hs-cTnI are given.  
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SUPPLEMENTAL FIGURE 3. Association of hs-cTnT (blue) and hs-cTnI (grey) with the coronary calcium score 
(CCS) (A), CCTA plaque severity (B), and echocardiographic parameters, LVEF (C) and LVH (D). *p-value <0.05 
in comparison with the non-diseased group. Pearson R correlation factors with the natural logarithm of hs-
cTnT and hs-cTnI are given. AS, indicates Agatston score 
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hs-cTnT 
 
hs-cTnI 
 
Determinant 
All  
patients 
≤7.2ng/L 
(N=231) 
>7.2ng/L 
(N=318) 
P- 
value 
≤2.6ng/L 
(N=163) 
>2.6ng/L 
(N=386) 
P- 
value 
Left ventricular  
ejection fraction,% 
60.0±7.3 60.7±5.9 59.4±8.2 0.037 60.8±5.5 59.6±8.0 0.056 
Left ventricular  
mass, g 
169.3±45.0 158±37 178±49 <0.001 155±34 176±48 <0.001 
Left ventricular  
mass index, g/m² 
87.4±20.0 83.2±16.6 90.7±21.8 <0.001 82.5±16.1 89.7±21.2 <0.001 
 
SUPPLEMENTAL TABLE 2. The presence (%) of CAD and renal dysfunction in patients with elevated hs-cTnT 
and hs-cTnI concentrations. 
 
 
 
 
 
 
 
SUPPLEMENTAL TABLE 3. Baseline characteristics of subpopulation (N=549/1876 patients) in which 
echocardiography was performed, by median hs-cTnT and hs-cTnI concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with hs-cTn > 
99th percentile cutoff 
Patients with hs-cTn > 
gender specific 99th percentile cutoff 
 Hs-cTnT (n=123) Hs-cTnI (n=40) Hs-cTnT (n=173) Hs-cTnI (n=45) 
 Percentage (n) Percentage (n) Percentage (n) Percentage (n) 
Obstructive plaque 42% (52/123) 38% (15/40) 39% (68/173) 36% (16/45) 
Obstructive plaque 
or CCS > 400 
47% (58/123) 43% (17/40) 43% (75/173) 42% (19/45) 
eGFR < 90 mL/min/1.73m² 53% (65/123) 30% (12/40) 61% (105/173) 27% (12/45) 
Obstructive plaque 
or CCS > 400 or 
eGFR < 90 mL/min/1.73m² 
72% (88/123) 58% (23/40) 75% (129/173) 56% (25/45) 
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SUPPLEMENTAL TABLE 5. Differences in baseline characteristics between cardiovascular event and event-
free group. 
 
 
Determinant Event (N=54) No event (N=1635) P-value 
Traditional risk factors   
Males, n (%) 39 (72.2%) 904 (55.3%) 0.014 
Age, years 59.7 ± 10.7 56.4 ± 10.8 0.010 
BMI, kg/m² 26.6 ± 3.5 27.0 ± 4.4 0.586 
Smokers, n (%) 39.7% 21.7% <0.001 
Diabetes, n (%) 7 (13.0%) 121 (7.4%) 0.129 
Fam. history, n (%) 17 (31.5%) 627 (38.3%) 0.307 
Systolic BP, mmHg 146.0 ± 17.5 142.7 ± 19.6 0.147 
Diastolic BP, mmHg 80.5 ± 11.7 80.0 ± 11.4 0.930 
Total cholesterol, mmol/L 5.2 ± 1.4 5.5 ± 1.2 0.318 
Cardiac biochemical markers   
hs-cTnT, ng/L 8.9 (6.5) 7.2 (3.3) 0.004 
hs-cTnI, ng/L 3.6 (7.4) 2.7 (2.4) 0.024 
Renal clearance    
Cystatin C, mg/L 0.86 ± 0.27 0.77 ± 0.18 0.006 
Creatinine, µmol/L 82.8 ± 21.8 74.8 ± 15.6 0.009 
eGFRcreat+cysC, mL/min/1.73m² 91.2 ± 21.0 98.6 ± 18.3 0.001 
CT/CCTA parameters   
Coronary calcium score, AS 206.3 (601.0) 4.8 (111.0) <0.001 
Moderate-to-severe plaque, n (%) 40 (74.1%) 375 (22.9%) <0.001 
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Abstract 
Background 
High-sensitivity cardiac troponins (hs-cTn) have proven to be valuable risk 
stratification tools in more general populations of older adults. In the present 
study we explore the value of measuring hs-cTn in geriatric care, by 
investigating the major determinants and prognostic importance of hs-cTnT and  
(hs)cTnI. 
Materials and methods 
495 residents from nursing homes (>65 years) of five healthcare organizations 
were examined. The residents underwent clinical and echocardiographic 
assessment for the diagnosis of heart failure. cTn was measured using high-
sensitivity (hs-)cTnT (Roche), hs-cTnI (Abbott) and less sensitive cTnI 
(Beckman) assays. The glomerular filtration rate was estimated (eGFR) using 
serum creatinine and cystatin C concentrations. Data on all-cause mortality 
were collected upon 1 year follow-up. 
Results 
Median (IQR) concentrations were 20.6(17.8-30.6) ng/L, 6.8(4.1-12.5) ng/L and 
4.0(2.0-8.0) ng/L for hs-cTnT, hs-cTnI and cTnI respectively. In total, 79% had 
elevated hs-cTnT concentrations, while only 9% and 5% of hs-cTnI and cTnI 
concentrations were elevated. Most important determinants for higher hs-cTnT 
and hs-cTnI concentrations were of cardiac and renal origin. Whereas both 
heart failure (OR:3.4) and eGFR<60mL/min/1.73m² (OR:3.6) were equal 
contributors to higher hs-cTnT concentrations (all p<0.001), hs-cTnI and cTnI 
were less associated to renal dysfunction (OR of respectively1.9 and 2.1; 
p<0.01) in comparison to heart failure (OR:4.3 and 4.7, respectively, p<0.001). 
Still, higher hs-cTnT concentrations were a better predictor for all-cause 
mortality compared to both (hs-)cTnI assays. 
Conclusion 
In frail nursing home residents, all hs-cTn assays were highly associated with 
heart failure, while hs-cTnT was more associated with renal dysfunction than 
both (hs-)cTnI. Despite this, hs-cTnT had a more prominent role in assessing 
the risk on all-cause mortality. 
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Introduction 
Older adults receiving long-term care in nursing homes are thought to have a 
high risk on chronic diseases such as heart failure, but still remain a poorly 
investigated population [1, 2]. Predicting those at risk for chronic diseases and 
mortality can therefore lead to preventive strategies and enhancements in their 
quality of life.  
Cardiac biomarkers, such as high-sensitivity cardiac troponins (hs-cTn) have 
proven to be valuable risk stratification tools in more general populations of 
older adults [3, 4] and are associated with the prevalence of cardiovascular 
diseases [5, 6]. Measuring hs-cTn is currently an essential component for the 
diagnosis of acute myocardial infarction (AMI) [7], in which the diagnostic cutoff 
is set at the 99
th
 percentile upper reference limit (URL) established in a healthy 
reference population [8, 9]. Elevated hs-cTn concentrations are however 
commonly found in the elderly [3, 10, 11] even when contributing comorbidities 
were excluded [12-15] and thereby challenging clinicians with the interpretation 
of these results [10]. These issues become even more important in frail older 
adults, such as nursing home residents. Therefore, age-specific cutoffs have 
been proposed [5, 10, 11, 15, 16], although they are currently not implemented 
in the guidelines [7, 17].  
In the present multicenter study on nursing home residents, we explore the 
value of measuring hs-cTnT and (hs-)cTnI in geriatric care. Major determinants 
and prognostic information of hs-cTn concentrations are evaluated in a well-
characterized and representative cohort of nursing home residents over 65 
years. Moreover, we examined whether higher cut-offs should be applied in 
these elderly and focus on the comparison between the results of hs-cTnT, hs-
cTnI and a sensitive cTnI assay. 
 
Materials and methods 
Study population 
In this study, 501 nursing home residents from five healthcare organizations in 
the Netherlands who receive long term care were examined.  Residents were 
eligible when over 65 years of age, not receiving palliative care and not admitted 
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for short-term rehabilitation (<2 months). Blood samples could not be drawn in 6 
residents, therefore data is presented for 495 subjects (SUPPLEMENTAL 
FIGURE 1). Information regarding comorbidities and current prescribed 
medication were retrieved from medical records, physical examinations and 
questionnaires. The presence of heart failure was assessed by a panel of two 
cardiologists and a geriatrician, who were blinded for (hs-)cTn results. The 
diagnosis of heart failure was based on clinical examinations (including history, 
physical examinations, electrocardiography, echocardiography and if in doubt 
NTproBNP concentrations), patient records and questionnaires. A detailed 
study protocol has been published previously [18]. One year after inclusion, 
medical records at the nursing home were searched again for the occurrence of 
all-cause mortality. Follow-up data was retrieved from 466 residents (94%) due 
to transfer to non-participating healthcare centres.  
This study was conducted according to the principles of the Declaration of 
Helsinki and approved by the local ethics committee. Written informed consent 
was obtained from all subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTAL FIGURE 1. Flow chart of included residents 
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Biochemical analysis 
Serum samples were collected, processed within 5 hours in aliquots and directly 
stored at -80 °C until analysis. Serum creatinine, cystatin C, NTproBNP and hs-
cTnT concentrations were measured on the Cobas 6000 analyzer (Roche 
Diagnostics, Mannheim, Germany). Creatinine concentrations were assessed 
using the enzymatic method (Roche Diagnostics). Cystatin C was measured 
using a particle-enhanced turbidimetric assay (Gentian AS, Moss, Norway), that 
was standardized against the certified ERM-DA471/IFCC cystatin C reference 
material [19]. The glomerular filtration rate was estimated by the Chronic Kidney 
Disease Epidemiology Collaboration [20] and the Berlin Initiative Study (BIS)-2 
equation [21], both using serum creatinine and cystatin C concentrations. Hs-
cTnT concentrations were determined using the high-sensitivity cTnT assay 
(Roche Diagnostics; lotnumber 167650), with a 99
th
 percentile upper reference 
limit of 14 ng/L and a 10% coefficient of variation (CV) cutoff at 13 ng/L and limit 
of detection (LoD) at 5 ng/L. Gender-specific cutoffs were reported at 14.5 ng/L 
and 10 ng/L for males and females, respectively [22]. Hs-cTnI measurements 
were performed on the ARCHITECT i2000SR platform using the precommercial 
ARCHITECT STAT high-sensitivity troponin I (hs-cTnI) assay (Abbott 
Laboratories, Hoofddorp, the Netherlands). According to the manufacturer, LoD 
and 10% CV cutoff were reached at 1.1-1.9 and 4.7 ng/L, respectively and the 
99
th
 percentile cut-off concentration for the overall population was at 26.2 ng/L. 
Gender-specific cut-offs at 34.2 ng/L and 15.6 ng/L were also defined for males 
and females, respectively.  Also, cTnI was measured using the guideline 
acceptable Access-3 TnI assay (Beckman Coulter) on the DXL platform. The 
99
th
 percentile and 10% CV cut-off concentration were both established at 40 
ng/L by the manufacturer. All biochemical analysis were performed in freshly 
thawed aliquots, except for Beckman cTnI results that were measured after one 
additional freeze-thaw cycle. 
Echocardiography analysis 
Echocardiography was performed by an expert echocardiographist, who was 
blinded for hs-cTn concentrations. Transthoracic images of the left ventricle (LV) 
were acquired to assess morphology, function and mass (Philips CX-50, Philips 
CHAPTER FOUR 
84 
 
Medical Systems, Best, the Netherlands). LV function and -mass were 
calculated by off-line image analysis using Xcelera software package (Philips 
Medical Systems, Best, the Netherlands), according to current ESC/AHA 
guidelines [23]. Left ventricular hypertrophy (LVH) was defined as an LVmass 
>95 g/m
2
 in females or LVmass >115 g/m² in males. Echocardiographic analysis 
could not be performed in 51 residents due to impaired image quality. 
Selection criteria of healthier subpopulations 
From the complete nursing home cohort (n=495), increasingly healthier subjects 
were selected using gradually more rigorous selection criteria. In Subgroup 1 
(n=322; 65%) all residents with heart failure, diagnosed during this study were 
excluded from the original cohort. In subgroup 2 (n=196; 40%) all residents with 
heart failure, LVH, LVEF<55% and NTproBNP concentrations >400 pg/mL (47 
pmol/L) were excluded. Subgroup 3 (n=154; 31%) encompassed the residents 
of subgroup 2, except for those with a history of cardiovascular events, defined 
as acute myocardial infarction, coronary artery disease, cardiac surgery or 
revascularisation procedures performed and prior stroke. Finally, subgroup 4 
(n=97; 20%) consisted of the residents of subgroup 3, excluding those with 
known impaired kidney functions or an eGFR<60 mL/min/1.73m².  
Statistical analysis 
Comparisons of baseline characteristics were performed using the T-test for 
continuous variables with a normal distribution, Mann-Whitney U-test for non-
normal distributed continuous variables and Chi square test for categorical 
variables. Data are presented as proportions, means ± standard deviations 
(SD), and data with a non-normal distribution are given as the median 
(interquartile range, IQR). Due to the low amount of (<300) residents in the 
increasingly healthier subpopulations, 97.5
th
 and 95
th
 percentile (hs-)cTn cutoffs 
were computed instead of the 99
th
 percentile URL. The 95% confidence 
intervals (CI) of the 97.5
th
 and 95
th
 percentile cut-offs were calculated using 
10.000 bootstrap samples. The relative contribution of renal function and heart 
failure to (hs-)cTn concentrations was assessed by logistic regression analyses 
with hs-cTnT, hs-cTnI or cTnI in the 4
th
 quartile as the dependent categorical 
variable. Furthermore, linear regression analysis and Pearson R correlations 
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were performed with the natural logarithm (Ln) of hs-cTnT and hs-cTnI as 
dependent categorical variable, to normalize their skewed distribution. The 
prognostic value of (hs-)cTn concentrations was investigated by univariable and 
multivariable Cox-proportional hazards models. Kaplan Meier plots were 
constructed to illustrate survival rates.  
Statistical analysis was performed with SPSS 20.0 (SPSS Inc, Chicago, IL, 
USA). Two sided p-values of <0.05 were considered statistically significant.  
 
Results 
Baseline characteristics and the association to (hs-)cTn concentrations 
In this study, participants were on average 82±7 years old and 64% was female. 
Of all residents with heart failure (34%), 48% of the residents suffered from 
heart failure with a reduced ejection fraction (LVEF<50%). An overview of other 
baseline characteristics is presented in TABLE 1. 
The distribution of baseline hs-cTnT and hs-cTnI concentrations is illustrated in 
FIGURE 1. Median (IQR) concentrations were 20.6 (17.8-30.6) ng/L, 6.8 (4.1-
12.5) ng/L and 4.0 (2.0-8.0) ng/L for hs-cTnT, hs-cTnI and cTnI respectively 
(TABLE 1). The results of the two cTnI assays were highly correlated (Pearson 
R(95%CI):0.884 (0.860-0.904), p<0.001), whereas associations between hs-
cTnT assay and either hs-cTnI (Pearson R (95%CI):0.580 (0.515-0.638); 
p<0.001) or the cTnI-assay (Pearson R (95%CI):0.548 (0.483-0.608); p<0.001) 
were significantly weaker. In total, 79% had elevated hs-cTnT concentrations 
(>99
th
 percentile), while only 9% and 5% of hs-cTnI and cTnI concentrations 
were elevated. When applying gender-specific cut-offs 89% and 16%, 
respectively, had elevated hs-cTnT and hs-cTnI concentrations.  
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All residents  
(n = 495) 
Traditional cardiovascular risk factors   
Age (years), mean (±SD) 82 (±7) 
Male gender, % 36% 
Body mass index, mean (±SD) 25.1 (±5.2) 
Hypertension, % 53% 
Diabetes mellitus, % 22% 
Hypercholesterolemia, %1 29%1 
smokers, % 14% 
History, n (%)  
Prior cardiac event (total) 33% 
Prior CAD (angina) 23% 
Prior myocardial infarction 16% 
Prior cardiac surgery (pacemaker, heart valve) 5% 
Prior revascularization (CABG, PCI) 10% 
Prior stroke (CVA) 41% 
Comorbidities, %  
Heart failure2 34% 
Impaired kidney function 12% 
COPD 17% 
Dementia 57% 
Medication use  
Statins 26% 
Beta-blokkers 30% 
Digoxin 8% 
Diuretics 39% 
ACE inhibitors 18% 
Nitrates 17% 
Ca-antagonists 12% 
Echocardiography2  
LVmass (g), mean (±SD) 137.2 (±51.8) 
LVMI (g/m²), mean (±SD) 78.5 (±26.7) 
LVEF (%), mean (±SD) 55.3 (±11.8) 
LVH, % 14%2 
Biochemistry  
NTproBNP (pmol/L), median (IQR) 48 (20–117) 
Creatinine (µmol/L), mean (±SD) 89.5 (±52.1) 
Cystatin C (mg/L), mean (±SD) 1.3 (±0.53) 
eGFRCKD EPI (creat-cys C) (mL/min/1.73m²), mean (±SD) 58.8 (±20.1) 
eGFRBIS-2 (mL/min/1.73m²), mean (±SD) 53.2 (±16.3) 
Roche hs-cTnT (ng/L), median (IQR) 20.6 (17.8–30.6) 
Abbott hs-cTnI (ng/L),  median (IQR) 6.8 (4.1–12.5) 
Beckman cTnI (ng/L), median (IQR) 4.0 (2.0–8.0) 
 
TABLE 1. Baseline characteristics of a cohort of aged nursing home residents. *, indicates more than 10% 
missing data. 
1data on hypercholesterolemia was present for 440 residents; 2 echocardiography results based 
on 444 residents 
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FIGURE 1. Distribution of hs-cTnTRoche, hs-cTnIAbbott and cTnIBeckman concentrations in aged nursing home 
residents. 
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TABLE 2. Median (IQR) hs-cTnT, hs-cTnI and cTnI concentrations in fragile elderly according to the presence 
or absence of traditional risk factors as well as heart and kidney dysfunction. 
 
 
 
 
 
Median (IQR) hs-cTnT 
(Roche) 
concentrations (ng/L), 
when determinant is: 
P-
value 
Median (IQR) hs-cTnI 
(Abbott) 
concentrations (ng/L), 
when determinant is: 
P-
value 
Median (IQR) cTnI 
(Beckman) 
concentrations (ng/L), 
when determinant is: 
P-
value 
Determinant not present present 
not 
present 
present 
not 
present 
present 
Male sex 
19.7 
(14.2–28.4) 
21.8 
(16.0–35.4) 
0.014 
6.5 
(4.1–12.6) 
7.2 
(4.4–12.3) 
0.337 
4.0 
(2.0–9.0) 
4.0 
(2.0–7.0) 
0.756 
Hypertension 
19.0 
(13.3–27.8) 
21.8 
(16.0–35.1) 
<0.001 
5.9 
(3.8–10.4) 
7.2 
(4.4–13.5) 
0.015 
4.0 
(2.0–7.0) 
4.0 
(2.0–9.0) 
0.212 
Diabetes 
20.0 
(14.5–30.0) 
22.2 
(15.7–36.2) 
0.044 
6.8 
(4.1–12.4) 
6.6 
(4.2–13.1) 
0.930 
4.0 
(2.0–8.0) 
4.5 
(2.0–9.0) 
0.529 
Hypercholesterolemia 
20.2 
(14.5–31.3) 
21.1 
(15.5–28.8) 
0.899 
7.1 
(4.1–12.7) 
6.3 
(4.4–11.1) 
0.264 
4.0 
(2.0–8.0) 
4.0 
(2.0–7.5) 
0.374 
Smoking 
21.0 
(15.0–30.7) 
18.4 
(12.6–30.5) 
0.227 
6.8 
(4.2–12.4) 
6.6 
(3.7–12.0) 
0.997 
4.0 
(2.0–8.0) 
3.0 
(2.0–7.0) 
0.811 
Prior cardiac event 
(total) 
19.3 
(14.1–28.3) 
23.4 
(16.5–35.9) 
<0.001 
5.9 
(3.8–10.5) 
8.3 
(5.2–18.4) 
<0.001 
3.0 
(2.0–7.0) 
6.0 
(3.0–12.0) 
<0.001 
Prior MI 
19.8 
(14.5–29.4) 
23.6 
(18.2–45.1) 
0.001 
6.3 
(4.0–11.4) 
8.2 
(5.8–19.2) 
<0.001 
4.0 
(2.0–7.0) 
6.0 
(3.0–12.0) 
0.001 
Prior stroke 
20.0 
(14.6–31.0) 
21.6 
(15.5–29.0) 
0.475 
6.4 
(4.1–11.3) 
7.3 
(4.1–13.7) 
0.501 
4.0 
(2.0–8.0) 
5.0 
(2.0–8.0) 
0.174 
COPD 
20.0 
(14.8–28.8) 
23.5 
(14.9–
3538) 
0.033 
6.4 
(4.1–11.3) 
10.0 
(5.0–17.5) 
0.017 
4.0 
(2.0–8.0) 
7.0 
(2.0–10.0) 
0.004 
Dementia 
21.8 
(16.4–33.0) 
19.5 
(14.3–28.3) 
0.008 
7.7 
(4.3–13.4) 
6.4 
(4.0–11.3) 
0.335 
5.0 
(2.0–8.0) 
4.0 
(2.0–7.0) 
0.020 
Heart failure 
18.6 
(13.2–25.4) 
26.4 
(18.7–43.8) 
<0.001 
5.1 
(3.6–8.5) 
11.4 
(7.2–20.3) 
<0.001 
3.0 
(1.0–6.0) 
7.0 
(4.0–16.0) 
<0.001 
HF reduced LVEF 
24.0 
(17.4-37.2) 
25.6 
(18.6-35.9) 
0.751 
11.1 
(7.0-18.9) 
11.6 
(6.6-19.1) 
0.947 
7 
(4.0-16.5) 
7 
(4.0-16.8) 
0.800 
LVH 
20.1 
(14.5–28.6) 
21.5 
(16.2–31.0) 
0.609 
6.4 
(3.8–11.4) 
5.9 
(4.1–10.7) 
0.010 
4.0 
(2.0–7.0) 
7.0 
(2.0–12.0) 
0.033 
LVEF<40% 
19.6 
(14.3–28.2) 
25.6 
(18.3–35.4) 
0.022 
6.4 
(3.8–11.0) 
11.4 
(5.7–22.3) 
0.008 
4.0 
(2.0–7.0) 
7.0 
(4.0–19.0) 
0.004 
LVEF<50% 
19.3 
(14.1–27.2) 
22.5 
(17.6–33.2) 
0.017 
6.3 
(3.7–10.4) 
9.6 
(5.1–18.4) 
0.005 
4.0 
(2.0–6.0) 
7.0 
(3.0–11.0) 
0.002 
Impaired kidney 
function 
19.9 
(14.5–28.5) 
28.9 
(19.4–54.9) 
<0.001 
6.5 
(4.1–11.4) 
7.8 
(4.8–20.6) 
0.013 
4.0 
(2.0–8.0) 
6.0 
(3.0–26.0) 
0.397 
eGFRcysC+Kre  
           < 60 mL/min 
18.0 
(13.2–23.2) 
25.2 
(16.8–36.4) 
<0.001 
5.1 
(3.7–8.7) 
8.1 
(4.8–16.6) 
<0.001 
3.0 
(1.0–6.0) 
6.0 
(3.0–11.0) 
<0.001 
eGFRBIS-2  
         < 60 mL/min 
18.1 
(13.3–23.3) 
25.2 
(16.8–36.5) 
<0.001 
5.6 
(4.2–9.9) 
12.4 
(7.5–25.5) 
<0.001 
3.0 
(1.0–5.0) 
5.0 
(2.0–10.0) 
<0.001 
Statins 
21.2 
(14.6–31.2 
19.8 
(15.2–28.6) 
0.858 
6.8 
(4.0–12.7) 
6.8 
(4.5–12.2) 
0.890 
4.0 
(2.0–9.0) 
4.0 
(2.0–7.0) 
0.559 
Beta-blokkers 
20.1 
(14.5–30.1) 
22.3 
(16.4–32.6) 
0.036 
6.4 
(3.9–11.3) 
7.9 
(4.7–16.4) 
0.009 
4.0 
(2.0–8.0) 
5.0 
(3.0–10.8) 
0.017 
Digoxin 
20.3 
(14.7–30.0) 
22.6 
(16.0–41.5) 
0.096 
6.4 
(4.1v11.4) 
14.9 
(7.0–22.6) 
<0.001 
4.0 
(2.0–8.0) 
10.0 
(5.8–33.8) 
<0.001 
Diuretics 
18.8 
(13.3–25.4) 
25.3 
(17.7–39.6) 
<0.001 
5.7 
(3.8–9.6) 
9.1 
(5.3–18.1) 
<0.001 
3.0 
(2.0–7.0) 
6.0 
(3.0–12.0) 
<0.001 
ACE inhibitors 
20.0 
(14.3–31.0) 
22.8 
(17.6–30.2) 
0.033 
6.3 
(3.9–11.9) 
8.4 
(5.7–14.0) 
<0.001 
4.0 
(2.0–8.0) 
6.0 
(3.0–9.5) 
0.005 
Nitrates 
20.1 
(14.6–29.7) 
22.5 
(15.5–36.0) 
0.079 
6.3 
(4.0–11.4) 
8.5 
(5.5–17.1) 
0.001 
4.0 
(2.0–8.0) 
6.0 
(3.0–12.5) 
0.002 
Ca-antagonists 
21.1 
(14.8–31.0) 
18.1 
(14.6–25.5) 
0.240 
6.8 
(4.1–12.6) 
6.9 
(4.9–10.9) 
0.969 
4.0 
(2.0–9.0) 
4.0 
(2.0–7.0) 
0.713 
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As depicted in TABLE 2, significantly higher concentrations for all cTn results 
(p<0.001) were found in residents with a cardiac event in their medical history, a 
reduced kidney function and on diuretics.  Also in residents with heart failure, 
higher (hs-)cTn concentrations were found although median (hs-)cTn 
concentrations were not statistically different in subjects with a reduced versus 
preserved ejection fraction (all p>0.05). Strikingly, higher hs-cTnT but not (hs-) 
cTnI concentrations were found in males compared to females, although only 
minor differences were observed. In contrast, (hs-)cTnI but not hs-cTnT were 
significantly higher in participants with LVH. 
(Hs-)cTn concentrations in subpopulations without cardiac, echocardiographic and renal 
abnormalities   
In the total cohort, 97.5
th
 (95%CI) percentile cutoffs were established at 83.9 
(71.2-108.1), 58.4 (40.8-123.8) and 52.0 (41.1-88.9) ng/L for hs-cTnT, hs-cTnI 
and cTnI respectively (FIGURE 2). These cutoffs decreased when subjects with 
heart failure and other cardiovascular diseases (subgroup 1-3) were excluded. 
As such, in residents without structural heart disease and prior cardiovascular 
events (subgroup 3) the 97.5
th
 percentile reduced to 62.8 (38.3-75.2), 25.7 
(16.6-45.6) and 19.7 (9.4-218.7) ng/L for hs-cTnT, hs-cTnI and cTnI, 
respectively.  
Additionally, excluding participants with renal dysfunction (subgroup 4) resulted 
in a further reduction in the 97.5
th
 percentile for hs-cTnT to 56.5 (33.1-78.4) 
ng/L, but did not affect hs-cTnI (25.9 ng/L) and cTnI (17.8 ng/L).  
Interestingly, 97.5 percentile cutoffs in all subgroups were substantially above 
the reported 99
th
 percentile URL for hs-cTnT (14ng/L), but not for both hs-cTnI 
(26.2 ng/L) and cTnI (40 ng/L), as depicted in FIGURE 2. Similar trends were 
seen for the 95
th
 percentile (hs-)cTn concentrations among the different 
subgroups (FIGURE 2).  
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FIGURE 2. 97.5% and 95% upper reference limits (95% confidence intervals) of hs-cTnT, hs-cTnI and cTnI in 
increasingly cardio-and renal healthier subpopulations. *, indicates that 95% CI were constructed using 
10.000 bootstrapping sample; Reported 99th percentile URL for each cTn assay are indicated with horizontal 
lines. 
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Association of (hs-)cTn concentrations with heart failure and renal dysfunction  
Univariable logistic regression analysis demonstrated that the presence of heart 
failure increased the odds of having hs-cTnT, hs-cTnI and cTnI concentrations 
in the 4
th
 quartile by 4.3, 4.9 and 5.4 times, respectively (TABLE 3; all p<0.001). 
Furthermore, the presence of renal dysfunction (eGFR<60mL/min/1.73m²) also 
accompanied with significantly higher (hs-)cTn concentrations, even beyond the 
presence of heart failure (TABLE 3; unadjusted multivariable model). Whereas 
both heart failure and decreases in eGFR were equal contributors to higher hs-
cTnT concentrations (OR of respectively 3.4 and 3.6, p<0.001), associations of 
hs-cTnI and cTnI with renal dysfunction were less pronounced (OR of 
respectively, 1.9 and 2.1; p<0.01) in comparison to heart failure (OR of 
respectively 4.3 and 4.7, p<0.001). The same results were found when linear 
regression analyses were performed (SUPPLEMENTAL TABLE 1-2).  
 
 
 
 
TABLE 3. Logistic regression analysis to assess the association of heart failure and eGFR to higher hs-cTn 
concentrations 
 
 
 
 
 univariable Unadjusted multivariable 
 OR  95%(CI) p-value OR  95%(CI) p-value 
Outcome variable: Roche hs-cTnT in 4th quartile (>30.4 ng/L) 
Heart failure 4.3 (2.8-6.5) <0.001 3.4 (2.2-5.4) <0.001 
eGFRCKDEPI < 60 mL/min/1.73m²  4.5 (2.8-7.3) <0.001 3.6 (2.2-5.9) <0.001 
Outcome variable: Abbott hs-cTnI in 4th quartile (>12.4 ng/L) 
Heart failure 4.9 (3.2-7.7) <0.001 4.3 (2.7-6.8) <0.001 
eGFRCKDEPI < 60 mL/min/1.73m²  2.6 (1.6-4.0) <0.001 1.9 (1.2-3.1) 0.007 
Outcome variable: Beckman cTnI in 4th quartile (>8.0 ng/L) 
Heart failure 5.4 (3.4-8.4) <0.001 4.7 (2.9-7.4) <0.001 
eGFRCKDEPI < 60 mL/min/1.73m²  2.9 (1.8-4.6) <0.001 2.1 (1.3-3.4) 0.003 
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Prognostic value of hs-cTn concentrations for all-cause-mortality. 
During the follow-up period of one year, 109 subjects (23.4%) died. These 
subjects were older, more frequently male and had a higher prevalence of heart 
failure and impaired kidney disease (SUPPLEMENTAL TABLE 3). Also, 
significantly higher hs-cTnT, hs-cTnI and cTnI concentrations were found in the 
residents that died. According 
to univariable Cox regression 
analysis, baseline hs-cTnT 
concentrations were a better 
predictor for all-cause mortality 
in comparison to both cTnI 
assays (FIGURE 3). Subjects 
with the highest hs-cTnT levels 
(4
th
 quartile) had a higher 
hazard ratio for all-cause 
mortality (HR = 1.8; p=0.004), 
compared to hs-cTnI (HR:1.3 
p=0.300) and cTnI (HR:1.6; 
p=0.041) concentrations. Even 
when adjusting for other 
significant risk factors baseline 
hs-cTnT remained superior in 
the prediction for all-cause 
mortality (SUPPLEMENTAL 
TABLE 4).  
 
 
 
 
FIGURE 3. Kaplan-meier curves for the 
estimation of risk on all-cause mortality 
using hs-cTnT, hs-cTnI and cTnI 
concentrations. 
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Discussion 
In this multicentre study we found that hs-cTnT concentrations are above the 
stated normal range, even in those without any cardiovascular and renal 
disease. This however is not the case of hs-cTnI and cTnI results. Moreover, 
employing hs-cTnT assays in geriatric care appears to be associated not only 
by cardiovascular diseases but also renal dysfunction. Despite this, hs-cTnT 
remained the most important prognostic factor for all-cause mortality. 
Hs-cTnT is more affected by age than (hs-)cTnI 
In this nursing home cohort, median hs-cTnI and cTnI concentrations were 
much lower than hs-cTnT. Intriguingly, the reported 99
th
 percentile cutoffs for 
both (hs-)cTnI assays are set higher than for hs-cTnT, even when established in 
the same reference population [9, 15, 24].  Consequently, more positive results 
were observed for hs-cTnT than (hs-)cTnI elevations. Since, 99
th
 percentile URL 
of hs-cTn are reported to be highly affected by age, gender and selection criteria 
of the reference population [24, 25], more cardiac and renal healthy subgroups 
were selected to gain more insight into the distribution of hs-cTn in these elderly 
subjects. Even in these healthier subpopulations, 97.5
th
 percentile hs-cTnT 
values were still at least 4 times higher as compared to the healthy reference 
population (URL at 14 ng/L), while around or below the reported URL for the hs-
cTnI (26.2 ng/L) and cTnI (40 ng/L) assays. It has been described that higher 
hs-cTn cutoffs give a better diagnostic performance in the elderly [5, 10, 11, 15]. 
This was especially true for hs-cTnT, with optimal cutoffs 4 to 5 fold higher as 
the established 99
th
 percentile URL in healthy reference populations (14 ng/L) 
[12, 26]. Together with our results, these findings imply that in elderly (>65 
years) a higher cutoff seems necessary for hs-cTnT, but might not be required 
for hs-cTnI.  
Hs-cTnT is more strongly associated with renal function than (hs-)cTnI   
The association with heart failure was equally as strong for all cTn assays. 
Remarkably, (hs-)cTnI appeared to be more associated with left ventricular 
function and morphology abnormalities than hs-cTnT in this cohort. However, 
both (hs-)cTnI and hs-cTnT results have been described to highly correlate with 
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left ventricular measures in the elderly [3, 4]. Therefore, more detailed head-to-
head comparisons between hs-cTnT and hs-cTnI assays should be performed 
to truly unravel these differences.  
Furthermore, we found that hs-cTnT was more influenced by renal dysfunction 
than hs-cTnI. By excluding residents with renal dysfunction, a visible effect on 
the reduction in hs-cTnT URL was noticed, which is in line with previous 
observations in other study populations [24, 27], but was not found for (hs-)cTnI. 
In chronic kidney disease patients, a higher association of eGFR with hs-cTnT 
in comparison to hs-cTnI has also been reported [28]. By examining the 
contribution of age, heart failure and renal dysfunction to hs-cTn concentrations, 
we are the first to identify the magnitude of these determinants. As such, we 
found in frail nursing home residents that hs-cTnT concentrations were equally 
associated by the presence of heart failure and renal dysfunction, whereas the 
correlation of both (hs-)cTnI concentrations with renal dysfunction was only half 
as strong as with heart failure. We are the first to describe this using two 
different cTnI assays, suggesting biological differences between the cTnT and 
cTnI molecules rather than assay-related analytical influences. A plausible 
explanation for these findings could be a slower clearance of cTnT from the 
blood circulation by the kidneys in comparison to cTnI. 
Hs-cTnT is a better predictor for all-cause mortality than (hs-)cTnI 
A stronger association with all-cause mortality was found for hs-cTnT in 
comparison to both hs-cTnI and cTnI, suggesting a more prominent role for hs-
cTnT in risk stratification. Notwithstanding, previous studies have clearly 
established the prognostic importance of hs-cTnI in the prediction for 
cardiovascular events and all-cause mortality [4, 12]. Our findings however do 
extend the results of previous work in acute populations where hs-cTnT 
outperformed (hs-)cTnI in its prognostic accuracy for the risk on all-cause 
mortality [27, 29, 30]. More recently, hs-cTnT appeared to have an additional 
prognostic importance independently from hs-cTnI [31], suggesting that hs-cTnT 
and hs-cTnI could contain different prognostic information. The rationale behind 
these findings could be the higher association of hs-cTnT with renal dysfunction. 
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Limitations 
Due to the small sample size, we were not able to compute the diagnostic cut-
off at the 99
th
 percentile concentration of the more healthier subgroups.  
Also, as the diagnosis of heart failure was assessed by an expert team, other 
clinical diagnoses were not. Echocardiographic analysis could however not be 
performed in 51 frail nursing home residents and subsequently the presence of 
heart failure could not be evaluated in these residents. 
 
Conclusion 
In summary, we challenge the application of the 99
th
 percentile cutoff in frail 
elderly (>65 years), especially for hs-cTnT. We found that hs-cTnT 
concentrations were elevated in almost all nursing home residents, in contrast 
to (hs-) cTnI concentrations, regardless from their cardiac and renal health. All 
hs-cTn assays were highly associated with heart failure and structural heart 
disease, while hs-cTnT was more associated with renal dysfunction than both 
(hs-)cTnI and had a more prominent role in assessing the risk on all-cause 
mortality. In daily practice, hs-cTnT and hs-cTnI results are used 
interchangeably to diagnose AMI. It however merits further research whether 
patients equally benefit from hs-cTnT and hs-cTnI measurements and as to 
whether such clinical benefit is dependent on age. 
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SUPPLEMENTAL TABLE 3. Associations of traditional risk factors, comorbidities, renal function and hs-cTn 
concentrations with the presence of all-cause mortality  
 
 
  
 
 
 
 
 All-cause-mortality 
Determinant Alive (n=357) Dead (n=109) p-value* 
Traditional cardiovascular risk factors 
Age (years), mean (±SD) 81.9±6.8 83.5±6.4 0.035 
Male gender, % 34% 48% 0.009 
Body mass index, mean (±SD) 25.6±5.3 24.2±5.3 0.011 
Smoking, % 14% 14% 0.926 
Systolic blood pressure, mean(±SD) 141.2±24.4 135.0±28.7 0.021 
Diastolic blood pressure, mean(±SD) 75.6±13.0 74.5±17.1 0.402 
Diabetes mellitus, % 21% 23% 0.632 
Hypercholesterolemia, % 27% 30% 0.926 
Prior cardiac event (total) , % 32% 38% 0.246 
Prior stroke (CVA) , % 39% 44% 0.315 
Comorbidities 
Heart failure, % 31% 43% 0.017 
Impaired kidney disease, % 10% 17% 0.066 
COPD, % 16% 20% 0.304 
Dementia, % 57% 57% 0.956 
(hs-)cTn concentrations    
Hs-cTnT concentrations (ng/L), median (IQR) 19.6 (13.9–29.1) 23.2 (16.8–41.0) 0.001 
Hs-cTnI concentrations (ng/L), median (IQR) 6.2 (3.9–12.1) 8.5 (5.6–16.7) 0.001 
cTnI concentrations (ng/L), median (IQR) 4.0 (2.0–8.0) 6.0 (3.0–13.0) 0.001 
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 HR (95%CI)  p-value 
Ln(hs-cTnT) (Roche) 
Model 1 1.58 (1.17–2.15) 0.003 
Model 2 1.50 (1.06–2.14) 0.024 
Ln(hs-cTnI) (Abbott) 
Model 1 1.10 (0.97–1.24) 0.139 
Model 2 1.06 (0.91–1.22) 0.467 
Ln(cTnI) (Beckman) 
Model 1 1.15 (1.02–1.29) 0.018 
Model 2 1.12 (0.98–1.23) 0.103 
 
SUPPLEMENTAL TABLE 4. Cox-regression analysis to examine the prognostic value of hs-cTnT (Roche), hs-
cTnI (Abbott) and cTnI (Beckman) for all-cause mortality when adjusted for significant risk factors. 
 
Model 1, adjusted for age, gender, BMI, systolic BP;  Model 2, adjusted for age, gender, BMI, systolic BP, 
presence of heart failure, presence of impaired kidney disease (medical history), eGFR. 
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Introduction 
Elevated concentrations of cardiac troponin T (cTnT; 37kDa) and I (cTnI; 
24kDa), and the N-terminal fragment of the prohormone brain-type natriuretic 
peptide (NTproBNP; 8.5kDa) have been reported in end-stage renal disease 
patients and are associated with cardiovascular morbidity and mortality [1, 2]. 
Also, cTnT, cTnI and NTproBNP correlate with glomerular filtration rate, 
suggesting a significant role of renal removal and consequences for the clinical 
interpretation of these cardiac markers [3]. The influence of hemodialysis (HD) 
on cardiac biomarkers itself remains contradictory. Previous studies have 
demonstrated intradialytic decreases [4] and increases in NTproBNP [5]. Also, 
significant reductions as well as increases in cTnT and cTnI concentrations 
have been reported following dialysis [5-8]. These differences can be attributed 
to the use of different dialysis modalities and membrane filters [5, 8]. 
Currently, most patients are treated with 4-hour high-flux HD. However, it has 
been shown that uremic toxins were better removed when patients were treated 
with hemodiafiltration (HDF) and extended 8-hour dialysis treatments resulted in 
more hemodynamic stability [9]. The aim of the present study was to assess the 
acute effects of conventional and extended high-flux HD and HDF on cardiac 
biomarkers in the same population as previously described [9], especially 
focusing on high-sensitivity (hs-) cTnT and  hs-cTnI results.  
Materials and methods 
Study population 
Prevalent conventional HD patients were recruited receiving chronic 
conventional HD treatments, without residual urine production and acute illness 
such as infection or cardiovascular events. All patients underwent one mid-week 
session in random order: 4-hour HD (HD4), 8-hour HD (HD8), 4-hour online 
HDF (HDF4) and 8-hour online HDF (HDF8) sessions; with a 2-week interval 
between the study sessions. Between the study sessions, these patients 
received conventional HD (HD4) treatments. All treatments were performed with 
the Fresenius 5008 Therapy System (Fresenius Medical Care). High-flux FX80 
and FX800 dialyzers (both Fresenius) were used for HD and HDF, respectively. 
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Blood flow and dialysate flow were 300 and 600mL/min, respectively. 
Substitution flow was 83.3mL/min to achieve a total substitution volume of 15L 
for HDF4 and 30L for HDF8. Dialysate composition was 1.5 mmol/L calcium, 2 
mmol/L potassium, 136-138 mmol/L sodium and 35-38 mmol/L bicarbonate and 
remain unchanged during the study period. This study 
(NL34908.068.10/MEC10-2-098) was approved by the local ethics committee, 
and written informed consent was obtained from each patient. 
Biochemical measurements 
Blood was drawn from the inlet bloodlines in serum tubes, immediately before 
and after dialysis. Serum samples were aliquoted, stored at -80°C and thawed 
prior to analysis. For HDF8, hs-cTnI and NTproBNP could not be measured in 3 
patients due to a lack of sufficient serum. cTnT was measured using the hs-
cTnT assay (Roche Diagnostics), with a limit of detection at 5ng/L and 10% 
coefficient of variation (CV) cutoff at 13ng/L and cTnI was measured with the 
ARCHITECT hs-cTnI assay (Abbott Diagnostics) with a limit of detection of 
2.3ng/L and 10%CV cutoff at 4ng/L. NTproBNP concentrations were assessed 
using the ProBNP-II assay (Roche) with a limit of detection of 0.6pmol/L and CV 
of 6.8% at 8.78pmol/L. Pre- and post-dialysis measurements were performed 
using the same assay on the same day. Post-dialysis concentrations were 
corrected for hemoconcentration by ultrafiltration using serum total protein and 
albumin measurements (Cobas 8000 analyzer, Roche Diagnostics). 
Statistical analysis 
Reduction ratios were calculated as follows: RR = [1–(pre-dialysis 
concentration/post-dialysis concentration)].  Differences in pre- versus post-
dialysis concentrations and reduction ratios (RR) were analyzed using the 
Wilcoxon signed rank test and pair-wise ANOVA, respectively. Two sided p-
values of <0.05 were considered statistically significant. Statistical analysis was 
performed with IMB SPSS 20.0 statistics program.   
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Results 
Baseline characteristics 
Thirteen patients completed the study, who were  on dialysis for a mean period 
of 49(±29) months.  Mean age of the patients was 53.6(±20.4) years and 10 
patients were males. During the study period, these patients were clinically 
stable. Additional specifications regarding this study are summarized in 
SUPPLEMENTAL TABLE 1 and have been previously published [9].  
 
SUPPLEMENTAL TABLE 1. Baseline characteristics as previously published by Cornelis et al [9] 
*P<0.05 versus HD4; § p<0.05 versus HDF4 
 
Influence of hemodialysis and hemodiafiltration on hs-cTnT, hs-cTnI and NTproBNP 
Median hs-cTnT concentrations were considerably higher than hs-cTnI 
concentrations before and after hemodialysis (TABLE 1). Moreover, all pre-
dialysis hs-cTnT concentrations were above the diagnostic cut-off of 14ng/L. In 
contrast, only three patients had elevated hs-cTnI concentrations (>26.2ng/L). 
Also, elevated NTproBNP concentrations (>35pmol/L) were measured in all 
patients.  
Characteristic HD4 HD8 HDF4 HDF8 
Effective dialysis time (min) 246±4 486±2*§ 245±3 487±6*§ 
Blood volume (L) 67.9±1.6 134.9±2.0*§ 68.5±1.1 135.3±1.4*§ 
Blood flow (mL/min) 283±7 287±4 286±5 288±3 
Dialysate flow (mL/min) 569±24 576±8 578±7 572±11 
Dialysate temperature (°C) 35.9±0.4 35.9±0.4 35.8±0.4 36.0±0.4 
Total ultrafilatration (L) 1.98±0.76 2.31±0.82 1.77±0.63 2.21±0.81 
Ultrafiltration rate (mL/h) 500±193 295±111*§ 449±160 265±83*§ 
Substitution volume (L) - - 14.6±1.1 29.7±0.4§ 
Single pool Kt/V 1.49±0.21 3.30±0.54*§ 1.60±0.30 3.34±1.05*§ 
Equilibrated Kt/V 1.36±0.26 3.09±0.51*§ 1.41±0.26 3.14±0.99*§ 
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Hs-cTnT modality 
hs-cTnTpre (ng/L); 
Median (IQR) 
hs-cTnTpost (ng/L); 
Median (IQR) 
p-value 
 
HD4 43.1 (36.1-62.8) 48.0 (31.4-77.1) 0.158 
HD8 41.6 (26.8-57.8) 35.9 (19.5-61.4) 0.534 
HDF4 46.0 (37.2-65.0) 41.8 (24.2-60.3) 0.013 
HDF8 44.1 (33.0-57.3) 33.9 (20.7-61.4) 0.004 
Hs-cTnI modality 
hs-cTnIpre (ng/L); 
Median (IQR) 
hs-cTnIpost (ng/L); 
Median (IQR) 
p-value 
 
HD4 11.4 (8.2-17.7) 12.6 (8.6-22.2) 0.347 
HD8 17.2 (7.4-26.5) 13.7 (6.7-24.0) 0.203 
HDF4 18.6 (7.0-24.6) 19.0 (6.1-29.1) 0.917 
HDF8* 22.4 (6.7-34.0) 12.8 (5.7-29.1) 0.028 
NTproBNP modality 
NTproBNPpre (pmol/L); 
Median (IQR) 
NTproBNPpost (pmol/L); 
Median (IQR) 
p-value 
 
HD4 427.3 (283.6-754.6) 407.2 (220.8-1112) 0.034 
HD8 393.0 (234.8-574.8) 218.2 (125.4-349.4) 0.008 
HDF4 458.9 (256.1-1170) 249.3 (117.3-591.4) 0.002 
HDF8* 308.6 (245.2-512.9) 102.2 (59.8-179.6) 0.008 
 
No significant differences were found between pre-dialysis hs-cTnT, hs-cTnI 
and NTproBNP concentrations for different dialysis-modalities (p>0.05). 
 
 
TABLE 1. hs-cTnT, hs-cTnI and NTproBNP concentrations pre and post dialysis, corrected for 
hemoconcentration, per modality. 
 
*based on serum samples of 10/13 patients 
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Generally, decreases in hs-cTnT, 
hs-cTnI as well as NTproBNP 
were found immediately after 
dialysis (TABLE 1). However, no 
significant differences were 
observed between pre- and post-
dialysis hs-cTnT and hs-cTnI 
concentrations after HD4 and HD8 
(TABLE 1; p>0.05). In contrast, 
HDF had a highly significant effect 
on hs-cTnT concentrations 
(p<0.01), especially following 
HDF8. Also hs-cTnI demonstrated 
a significant decrease after HDF8 
but not HDF4 (TABLE 1). For 
NTproBNP, significant intradialytic 
decreases following all modalities 
were observed, with the highest 
reduction after HDF8 (TABLE 1 
and FIGURE 1). 
When comparing HD4 to HDF8, 
more patients demonstrated a 
significant (>10%) decrease in hs-
cTnT, hs-cTnI and NTproBNP 
concentrations following HDF8  
(SUPPLEMENTAL FIGURE 1). 
 
 
SUPPLEMENTAL FIGURE 1. Individual changes 
in hs-cTnT, hs-cTnI and NTproBNP 
concentrations following either HD4 and 
HDF8-treatments. Full lines indicate a >10% 
decrease pre versus post-dialysis, while dotted 
lines indicate less than 10% reduction.  
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For hs-cTnT, significantly higher RRs were established following HDF compared 
to HD (FIGURE 1). Interestingly, RR were significantly higher for hs-cTnI after 
HD8 and HDF8 in comparison to HD4 and HDF4. Overall the highest RR were 
obtained following HDF8, although mean RR were still lower for hs-cTnT 
(20.4±8.8%) and hs-cTnI (23.0±16.2%) in comparison to NTproBNP 
(64.2±9.5%) and other uremic toxins (50-90%; [9]).  
 
 
FIGURE 1. Mean (±SD) reduction ratios of hs-cTnT, hs-cTnI and NTproBNP, corrected for hemoconcentration, 
following 4 and 8 hour hemodialysis and hemodiafiltration.  
 
 
Identical results were found when hs-cTnT, hs-cTnI and NTproBNP 
concentrations were corrected for hemoconcentration by ultrafiltration using 
albumin concentrations (data not shown). 
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Discussion 
This is the first study to reveal the effects of extended hemodialysis and 
hemodiafiltration on cardiac markers. Here, we clearly demonstrate a significant 
reduction in hs-cTnT, hs-cTnI and NTproBNP concentrations following HDF, 
although RR remained relatively low for both hs-cTn measurements (<25%).  
Recently it was shown that hs-cTnT concentrations display a diurnal variation, 
with peak hs-cTnT concentrations in the morning that gradually decrease during 
the day [10]. Herein, we found higher RR for hs-cTnT following 4 hour HDF in 
comparison to 8 hour HD. Consequently, we can conclude that dialysis 
treatments have an additional effect on hs-cTnT concentrations. However, 
whether these cTn reductions are due to clearance, still has to be elucidated by 
measuring in dialysate samples.  
Interestingly, the reduction of cTnT was more influenced by the use of 
convection in comparison to cTnI [9]. In addition, 8-hour dialysis treatments had 
the largest effects on the RR of cTnI. Whether this is the consequence of 
differences in cTn release or in clearance from the blood stream merits further 
research.  
In conclusion, this study demonstrated a clear effect of different dialysis 
modalities on cardiac biomarkers with highest RR’s during HDF8. Clinicians 
should be aware of this intradialytic reduction in cardiac biomarkers when 
interpreting serial results, especially in the diagnostic context of an acute 
myocardial infarction. The long-term effects of these dialysis modalities on the 
levels of cardiac biomarkers should be addressed in future studies.  
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Abstract     
Background 
Cardiac troponin T (cTnT) is widely used for the diagnosis of acute myocardial 
infarction (AMI). However, it is still unclear whether degraded cTnT forms 
circulate in the patient’s blood. We therefore aimed to elucidate which cTnT 
forms are detected by the clinical assay.  
Methods 
Separation of cTnT forms by gel filtration chromatography (GFC) was performed 
in sera from 13 AMI patients to examine cTnT degradation. The GFC eluates 
were subjected to Western blot analysis, using the original antibodies from the 
Roche immunoassay to mimic the clinical cTnT assay. To investigate the 
degradation pattern with time, standardized serum samples of 18 AMI patients 
collected 0-72 hours post-admission were analyzed by Western blot analysis.   
Results 
GFC analysis of AMI patients’ sera revealed two cTnT peaks with retention 
volumes of 5 and 11 mL. Western blot analysis identified these peaks as cTnT 
fragments of 29 and 14-18 kDa, respectively. Furthermore, the performance of 
direct Western blots on standardized serum samples, demonstrated a time-
dependent degradation pattern of cTnT, with fragments ranging between 14 and 
40 kDa. Intact cTnT (40 kDa) was only present in 3 patients within the first 8 
hours after hospital admission.  
Conclusion 
These results demonstrate that the Roche cTnT immunoassay detects intact as 
well as degraded cTnT forms in AMI patients’ sera during the period of 
diagnostic testing. Moreover, following AMI, cTnT is degraded in a time-
dependent pattern.  
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Introduction 
Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are superior to other 
cardiac markers because of their unique cardiospecificity. Consequently, they 
are considered to be the biomarkers of first choice to diagnose and monitor an 
acute myocardial infarction (AMI) [1]. Owing to patent restrictions only one cTnT 
assay (Roche Diagnostics) is currently commercially available, as compared 
with over twenty different assays for cTnI [2]. In addition, according to a recent 
survey, the Roche cTnT assay is used in half of European laboratories [3]. 
Therefore, characterization of cTnT, as detected by this assay, is important to 
better define its role in clinical decision making.  
The cTn T-I-C complex is structurally bound predominantly to the myofibrils with 
only a minor fraction of cTnT and cTnI (6-8%) present in the cytoplasm as 
soluble intact protein [4, 5], although this finding has been disputed [6]. 
Typically, AMI patients undergoing rapid reperfusion demonstrate a first cTnT 
peak concentration within 24 hours after onset of symptoms, which has been 
attributed to the fast release of cytosolic cTnT [4, 7]. This peak is followed by a 
second and persistent cTnT elevation which remains present for 7-14 days and 
is generally thought to represent the relatively slow dissociation of cTnT from 
the sarcomeres and release from the cells during necrosis. There is limited 
knowledge on the posttranslational modifications of cTnT after myocardial 
damage, in particular degradation of cTnT. On the other hand, degradation 
products of cTnI have been extensively reported [8-11]  and even associated 
with post-ischemic contractile dysfunction [12, 13].  
Previously, we have reported the presence of cTnT fragments on Western blots 
of human serum from renal failure and post AMI patients using different 
antibodies as the clinical assay [14, 15]. Other investigations have not 
confirmed these findings and found only intact cTnT on gel filtration 
chromatography (GFC) of serum from such patients [16, 17]. To date it is still 
not clear which cTnT forms circulate in the serum of AMI patients and if they are 
detected by the Roche cTnT assay.  
In this study, we aimed to elucidate whether degraded cTnT forms are present 
in the circulation following ischemic myocardial damage. We examined AMI 
patients’ sera using a novel approach. Firstly, the patients’ sera were 
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fractionated by GFC, as in previous studies [16, 17]. Secondly, these GFC 
fractions were subjected to a unique Western blotting technique, in which the 
capture and detector antibodies of the commercial cTnT assay were 
incorporated to mimic the working principle of this assay. In a second AMI 
population, we aimed to characterize the changes of the molecular forms of 
cTnT with time. Serum samples collected for each patient at standardized time 
points after symptom onset were subjected directly to this Western blotting 
technique.  
 
Materials and Methods 
Study populations 
GFC followed by Western blotting was performed on residual serum samples 
from 13 patients with acute myocardial infarction followed by rapid 
revascularization. Blood samples were obtained from the routine laboratory at 
two time points 3 (±1) as well as 15 (±2) hours after admission to the emergency 
department of Maastricht University Medical Center) and frozen at -80°C. One 
serum sample was missing from each of two AMI patients, one at 3 hours and 
one at 15 hours post-admission. As a result, 12 AMI serum samples were 
analyzed for both time points.  
The molecular changes of cTnT with time and their subsequent effect on infarct 
size estimation were examined in a second well-characterized AMI population. 
Serum samples of 18 ST-segment elevation myocardial infarction (STEMI) 
patients were collected at hospital admission and at standardized time points: 4, 
8, 12, 24, 36, 48, 60, and 72 hours after hospital admission and immediately 
stored at -80°C. These patients were enrolled in the control group of a clinical 
trial investigating the effects of ventricular pacing during revascularization, and 
thus receiving standard treatment (http://clinicaltrials.gov/ 
ct2/show/NCT00409604). Inclusion criteria for the study were as follows: age 
>18 years, presentation with their first myocardial infarction, admitted to hospital 
3 (±1) hours from symptom onset, treated with percutaneous coronary 
intervention (PCI) and exhibiting a typical release pattern of cTnT, creatine 
kinase (CK) and lactate dehydrogenase (LD).  
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The study was conducted according to the principles of the Declaration of 
Helsinki and approved by the local ethics committees. Informed consent was 
obtained from the patients.  
Biochemical testing 
cTnT was measured on the Elecsys 2010 (Roche) using the 4th generation 
cTnT assay with a limit of detection <0.01 µg/L and 10% CV cutoff at 0.03 µg/L. 
NT-proBNP was also measured on the Elecsys 2010 (Roche) with limit of 
detection 5.08 ng/L (0.6 pmol/L) and inter-assay CV 6.8% at 74.4 ng/L (8.78 
pmol/L). Albumin was measured on the Synchron LX20 (Beckman Coulter) 
using the microalbumin assay with measuring range of 2.0-970 mg/L. CK and 
LD were measured on the Synchron LX20 (Beckman) as well. cTnI was 
measured using the Axsym troponin I-Adv assay (Abbott Laboratories) with the 
10% CV cutoff at 0.16 µg/L. All assay characteristics were given by the 
manufacturer.  
Fractionation by GFC 
GFC was performed on a HP 1100 system (Agilent Technologies) equipped with 
a 1.6x60 cm Sephacryl-S100 column (GE Healthcare) and a diode array 
detector. The column was equilibrated with 0.26 mol/L NaCl, 2.5 mmol/L CaCl2 ∙ 
2 H2O, 0.02 mol/L Tris, 6 mmol/L NaN3 and 1g/L bovine serum albumin buffer, 
pH 7.4 [16] and operated at 0.5 mL/min. The void volume (V0) determination 
and calibration was conducted using the Gel Filtration Calibration kit (GE 
Healthcare) containing Dextran Blue (molecular weight (MW), 2000 kDa), 
conalbumin (MW, 75.0 kDa), ovalbumin (MW, 43.0 kDa), carbonic anhydrase 
(MW, 29.0 kDa) and ribonuclease (MW, 13.7 kDa), supplemented with 
myoglobin (MW, 16.9 kDa, Sigma). Dextran Blue (1 mg/ml) and globular protein 
standards (3-4 mg/ml) were dissolved in running buffer, 0.5 mL was loaded on 
the column, and absorbance was studied at 280 nm, all in duplo. V0 was 
determined to be 37 mL. 
In addition, purified human cTn T-I-C complex (MW, 77 kDa; Hytest) and 
purified free cTnT, cTnI, and troponin C (TnC) (MW, 37, 24 and 18 kDa, 
respectively; all Advanced ImmunoChemical) were dissolved as prescribed by 
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the manufacturer and were further diluted in running buffer or spiked in serum 
pool of healthy volunteers (cTnT < 0.01 µg/L and cTnI < 0.03 µg/L).  
To obtain the standard calibration curve, the gel-phase distribution coefficient 
(Kav= VR/(Vc-V0) ) was plotted against the logarithm of MW of globular proteins 
and purified cTn standards. VR signifies the retention volume adjusted to void 
volume, while Vc indicated column volume and corresponded to 120 mL.  
For serum samples, 1.0 mL was loaded on the column. Serum albumin (67 kDa) 
and serum NT-proBNP were used as internal standards in the patients’ sera. 
For each sample loaded, fractions of 1.25 mL were collected, kept on ice until 
immunoassay measurements (≤ 1 hour) and subsequently stored at -80°C.  
Purification and Western blot detection of cTnT 
Purification and characterization of cTnT was performed using the antibodies 
from the Roche cTnT-assay (as kindly provided by Roche Diagnostics, 
www.roche.com). The capture cTnT antibody (M11.7, epitope a.a.r. 136-147) 
was used for immunoprecipitation of cTnT. To each mL of magnetic 
streptavidin-coated dynabeads (Invitrogen) 10 µg biotinylated M11.7 was 
added. Additionally, beads were crosslinked three times with dimethyl 
pimelimidate. Subsequently, 200 µL of serum was precipitated with 50 µL of 
M11.7-coated beads for 1 hour at 4°C. Due to low cTnT concentrations in the 
GFC fractions, more sample was added to the beads, ranging from 200–5000 
µL. In some cases, up to 4 fractions were merged to generate larger volumes. 
The average cTnT yield after immunoprecipitation was >90% (data not shown). 
After being washed with PBS containing 0.1% Tween-20 (PBST) the 
immunoprecipitates were eluted with 1 M glycine (18 µL), pH 3 for 15 min at 
56°C. (SUPPLEMENTAL FIGURE 1) 
As negative controls for immunoblotting of GFC samples and AMI patients’ sera, 
running buffer or the serum pool of healthy volunteers was used, respectively. 
As positive controls, cTn T-I-C complex was spiked in running buffer and cTnT 
negative pooled serum, respectively. Only GFC fractions containing sufficiently 
high cTnT concentrations could be visualized on the immunoblot, corresponding 
to 9 out of 12 serum samples collected at ±15 hours post admission. 
Immunoprecipitates were diluted with XT Sample Buffer (6 µL) (Bio-Rad 
Laboratories), heated for 7 min. at 56°C, and separated on a 12% Criterion XT 
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SDS-PAGE gel (Bio-Rad) together with the Precision Plus Protein Standard 
(Bio-Rad). After stacking for 15 min at 100 V the proteins were resolved for 45 
min at 200 V in XT MOPS electrophoresis buffer (Bio-Rad) and were transferred 
to the nitrocellulose membrane (Bio-Rad, 0.45 µm) at 100 V for 1 h at 4°C. The 
membranes were treated with the vacuum SNAP i.d. protein detection system 
(Millipore) according to manufacturer instructions. Non-specific binding was 
blocked with 0.5% non-fat dry milk Blocking-Grade Blocker (Bio-Rad) in PBST. 
Primary and secondary antibodies were Roche M7 anti-cTnT antibody (epitope 
a.a.r. 125-131; 10 µg/L) and goat anti-mouse peroxidase (0.4 µg/mL; DAKO) in 
PBST, respectively. Subsequently, membranes were incubated for 5 minutes in 
Super Signal West Femto Substrate (Thermo Scientific) and bands were 
detected using the ChemiDoc XRS scanner (Bio-Rad) and Quantity One 
Software (Bio-Rad, Version 4.6.5.).  
Statistical Analysis 
Results are presented as means (± SD) or when not normally distributed as 
medians (interquartile range (IQR)). The Wilcoxon signed rank test was applied 
to investigate differences in peak-to-peak ratios of the GFC elution profiles 
obtained 3 and 15 hours post-admission. All statistical analyses were performed 
using SPSS (Statistical Package for Social Sciences; version 18). A p-value 
<0.05 was regarded as statistically significant.  
 
Results 
Validation of cTnT degradation by GFC followed by Western blotting  
Elution profiles of globular protein standards (MW varying from 16.9 to 75.0 
kDa) and purified cTn standards (cTn T-I-C complex, free cTnT, cTnI and TnC) 
were determined. A schematic overview of the obtained retention volumes 
adjusted to V0 (VR) is given in FIGURE 1A.  
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FIGURE 1. Validation of GFC analysis. (A) Schematic overview of the retention volumes obtained for purified 
cTn standards (cTnT-I-C, cTnT, cTnI, TnC), globular proteins and internal serum standards (serum albumin 
and NT-proBNP). (B) Standard calibration curve obtained with globular proteins (●) and purified cTn 
standards (▲). The gel-phase distribution coefficient (Kav=VR/(Vc-V0); Vc=column volume) was plotted 
against the log molecular weight (MW).  
 
When spiking the intact cTnT standard in cTnT-negative serum (cTnT, 19.9 
µg/L), cTnT elutes with VR of 5 mL before the elution of the internal standard 
serum albumin (VR = 11 mL) (SUPPLEMENTAL FIGURE 2A). Western blotting 
of these GFC fractions confirmed that this peak corresponded to intact cTnT 
(estimated MW, MWest of 40 kDa) and for a small part to 29 kDa cTnT fragment, 
as shown in SUPPLEMENTAL FIGURE 2B. An identical elution profile and 
immunoblot analysis were obtained when the purified cTnT standard was spiked 
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in running buffer (data not shown). For the other purified cTn standards, VR was 
determined to be 3 mL, 16 mL and 20 mL for the cTnT-I-C complex, intact cTnI 
and TnC, respectively. (FIGURE 1A) Moreover, the correlation between VR and 
MW of the globular proteins can be represented by a linear calibration curve 
following the equation y = -0.44x+0.93, as depicted by FIGURE 1B. In contrast, 
all cTn proteins (cTnT-I-C complex, free cTnT, cTnI and TnC) deviated clearly 
from the calibration curve. 
Median (IQR) cTnT concentrations measured in serum of AMI patients, 
subjected to GFC, were 2.17 (5.07) µg/L and 6.94 (6.46) µg/L for 3 and 15 hours 
post-admission, respectively. After GFC separation, overall median (IQR) 
recovery of loaded cTnT (%) was 79 (27) % (SUPPLEMENTAL TABLE 1). The 
GFC elution profiles of each patient showed two cTnT peaks at an adjusted VR 
of 5 and 22 mL, eluting before and after the internal standard serum albumin (VR 
= 11 mL). As shown in FIGURE 2A and 2B this was observed at 3 as well as 15 
hours post-admission, respectively. Western blot analysis using the antibodies 
of the clinical immunoassay identified the first cTnT peak at VR of 5 mL as a 
degradation product of cTnT with a MWest of 29 kDa (FIGURE 2C and D). The 
second peak (VR = 22 mL) was allocated to smaller cTnT degradation products 
of MWest between 14 and 18 kDa. Moreover, there was a significant relative 
increase in the second peak at 15 hours post admission as compared with 3 
hours post-admission (median ratio of cTnT-peak at 22 mL/5 mL of 0.54 and 
1.89 for 3 and 15 hours post-admission respectively; P= 0.001), suggesting a 
different cTnT degradation pattern that changed with time. 
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FIGURE 2. GFC analysis of AMI 
patients’ sera.  Elution profiles of 
AMI patients’ sera obtained at (A) 3 
and (B) 15 hours post-admission. 
Median (black) and IQR (grey) cTnT 
concentrations are shown. Serum 
albumin and serum NT-proBNP 
were used as internal standards. 
(C) cTnT Western blot of the 
fractions of a representative AMI 
serum sample obtained 15 hours 
after hospital admission.  P, 
positive control; M, marker; N, 
negative control. (D) Summary of 
the molecular forms of cTnT 
present in AMI serum samples 
collected 15 hours after hospital 
admission. Each dot represents a 
band on the Western blot of a 
patient. 
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Time course of cTnT degradation at standardized time points  
The release kinetics of cTnT, CK and LD determined in eighteen STEMI 
patients (66% males with mean(SD) age 60(9) years (see SUPPLEMENTAL 
TABLE 2) are shown in FIGURE 3A and SUPPLEMENTAL FIGURES 3 and 4, 
respectively. On average, peak cTnT concentrations were reached 8 hours after 
admission, with a median (IQR) concentration of 6.68 (4.54) µg/L. Furthermore, 
cTnT levels were still elevated 72 hours post-admission with a median (IQR) 
concentration of 2.65 (1.83) µg/L.  
FIGURE 3B depicts a representative blot of an AMI patient showing that the 
antibodies of the clinical assay detected mainly cTnT degradation products in 
the circulation. As many as five different degradation products were 
reproducibly identified (MWest of 14, 16, 18, 27 and 29 kDa). Moreover, a 
breakdown pattern of cTnT was observed over time. Western blot analysis of all 
patients showed that intact cTnT (MWest of 40 kDa) was present only in three 
patients during the first 8 hours after admission (FIGURE 3C). Instead the 29 
kDa fragment of cTnT was detected in highest abundance up to 24 hours post-
admission. Afterwards, the larger fragments (MWest of 27 and 29 kDa) 
disappeared and primarily low-molecular weight fragments between 14 and 18 
kDa were identified. When blotting with an antibody directed against the C 
terminus of cTnT, the same degradation pattern for cTnT was visualized. 
(SUPPLEMENTAL FIGURE 5) On the contrary, when applying an antibody 
directed against the N terminus of cTnT, none of the cTnT fragments were 
detected.  
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FIGURE 3. Time course of cTnT degradation at standardized time points. (A) Release kinetics of cTnT in AMI 
patients represented by the median (black) and IQR (grey) cTnT-concentrations. (B) cTnT Western blot of 
serum samples obtained at standardized time points of a representative AMI patient P, positive control; M, 
marker; N, negative control. (C) Summary of the molecular forms of cTnT present after AMI at the 
standardized time points. Each dot represents a band on the Western blot of a patient. 
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Discussion 
The present study shows for the first time that circulating cTnT is highly 
degraded in cases of AMI followed by rapid revascularization, as demonstrated 
by fractionation of serum from AMI patients with GFC and Western blotting, 
using the antibodies of the clinical cTnT assay.  
GFC enables detailed characterization of non-covalent complexes present in 
the patient’s serum, but also requires extensive and careful validation. Herein, 
we report similar elution profiles as previously found by Bates and colleagues 
[16], although they assigned their main peak to intact cTnT. As determined from 
the calibration curve, obtained with globular protein standards, the expected 
adjusted VR for intact cTnT would be 20 mL. However, in this study we clearly 
demonstrate that purified cTnT, and also other cTn molecules, eluted much 
earlier and therefore deviated from the calibration curve. For this reason, 
molecular weight assignment of cTn elution profiles should not be based on the 
molecular weights of globular proteins. This is especially important for elongated 
shaped structures like cTnT [18, 19]. In the present study, we identified that the 
most abundant form of circulating cTnT detected by the cTnT immunoassay is 
actually a mixture of cTnT fragments. Previous findings have also postulated 
that ternary structures of the cTn complex are the most frequent form present in 
the patient’s circulation [7, 16, 17, 20]. Using the same gel filtration technique 
[16, 17] we observed that this type of GFC column was not suitable for adequate 
separation of ternary bound cTn T-I-C complex (VR = 3 mL) and intact cTnT (VR 
= 5 mL) molecules. Therefore, the presence of ternary bound cTn molecules in 
the patient’s circulation requires further study.  
Furthermore, sera from AMI patients, drawn at standardized time points after 
admission to the emergency department, and analyzed directly with Western 
blot analysis revealed that cTnT is degraded in a time-dependent pattern. Intact 
cTnT was the largest cTnT form that could be detected and it was only present 
during the early hours (4 to 8 hours) after admission in three of the eighteen 
patients. Primarily 29 kDa cTnT fragments were visible up to 24 hours after AMI, 
corresponding to the peak concentrations of the cTnT release curve and the 
period of diagnostic testing. Later on, 29 kDa fragments seemed to diminish and 
degradation products with a smaller molecular mass (MWest of 14 and 16 kDa) 
CHAPTER SIX 
 
128 
 
dominated in peripheral blood. The immunoreactivity on the Western blot 
however seemed to differ between intact and low-molecular weight cTnT 
molecules, thereby limiting quantification of Western blot bands.  
Since, Roche Diagnostics is the only manufacturer of clinical cTnT assays, cTnT 
degradation does not affect harmonization between different assays, as 
previously reported for the cTnI assays [11]. To ensure quality of the cTnT 
measurement in blood samples, Roche Diagnostics recommends the use of 
recombinant human cTnT spiked in a human serum matrix for monitoring the 
calibration and precision of the assay.  However, as shown in the present study, 
this recombinant intact cTnT is not representative for AMI patient serum which 
contains mainly cTnT fragments. Furthermore, although studies have indicated 
the magnitude of cTnT measurements to be of prognostic value [21-23] and 
strongly correlated with infarct size [24, 25], whether the detection of different 
cTnT forms will affect the clinical utility of cTnT measurements has to be 
examined. 
A limitation to this study is that the 4th generation cTnT assay was used. 
However, the epitopes of the capture and detection antibody are the same for 
the current hs-cTnT assay [26]. Subsequently, the same cTnT forms will be 
detected by both assays. As cTnT fragments were observed using two different 
techniques and cTnT degradation exhibited a time-dependent pattern, these 
fragments are unlikely to have been introduced by our methodology, and the 
time-dependent pattern suggests they are the products of an enzymatic 
process. Moreover, when the purified cTn T-I-C standard (NIST-SRM 2921) was 
spiked into serum or heparin plasma, cTnT was shown not to be susceptible to 
degradation when stored for 72 hours at 4°C or for 24 hours at 37°C [27, 28].  It 
should be noted that the NIST-SRM 2921 standard  originally contained the 29 
kDa fragment of cTnT before incubation. These finding further suggests that the 
cTnT degradation observed in this study is induced in vivo. In addition, several 
in vitro studies have demonstrated that the degradation of cTnT occurred upon 
ischemia, due to the activity of calpain-I  [29-31] and caspase-3 [32] in the 
intracellular environment of cultured cardiomyocytes, possibly leading to the 
cleavage of the N terminus of cTnT. This all leads to the intriguing question of 
what modification patterns of cTn are present when myocardial necrosis is 
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thought to be absent, for instance after physical activity [33, 34], and the 
subsequent question of whether the diagnostic potential of cTnT can be further 
improved. Of note, the present study describes cTnT degradation in serum of 
AMI patients; the presence of cTnT fragments in heparin plasma samples has 
yet to be investigated. 
In conclusion, this study demonstrates that circulating cTnT undergoes 
degradation in serum following AMI and the degradation pattern is dependent 
on time after symptom onset. Importantly, this is the first study to reveal that the 
cTnT immunoassay widely applied in the clinic binds both intact as degradation 
products of cTnT during the time frame of diagnostic testing.  
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SUPPLEMENTAL FIGURE 1. Optimization of the elution procedure during immunoprecipitation. Troponin T-I-
C complex spiked in cTnT-negative serum was immunoprecipitated in triplo according to the methods 
described in the manuscript. Three different elution conditions were tested: (A) 1M glycine pH3 at 56°C (B) 
XT sample buffer (BioRad) at 95°C and (C) at 56°C.  
 
 
SUPPLEMENTAL FIGURE 2. GFC analysis of purified cTnT (A) Chromatographic curve for purified free cTnT 
spiked in cTn-negative serum; serum albumin (VR = 11 mL) and serum NT-proBNP (VR = 22 mL) were used as 
internal standards. (B) Purification and detection of cTnT by means of the cTnT antibodies of the clinical 
assay in the obtained chromatographic fractions. P, positive control; M, marker; N, negative control.  
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SUPPLEMENTAL FIGURE 3. Release kinetics of creatine kinase (CK) after AMI (n=18), represented by the 
median (black) and IQR (grey) concentrations of CK. U/L indicates units per liter. 
 
 
 
 
SUPPLEMENTAL FIGURE 4. Release kinetics of lactate dehydrogenase (LD) after AMI (n=18), represented by 
the median (black) and IQR (grey) concentrations of LD. U/L indicates units per liter. 
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SUPPLEMENTAL FIGURE 5. Western blot analysis using different cTnT antibodies. Two serum samples (S1 
and S2) immunoprecipitated in triplo with and loaded on the SDS-PAGE gel according to the specifications 
given in the methods section. Each Western blot was subsequently stained with different cTnT antibodies, 
namely (A) Roche detection antibody (M7); (B) antibody directed against N terminus of cTnT (1 µg/mL, 9G6, 
Hytest Ltd) and (C) the C terminus of cTnT (1 µg/mL, 7A9, Hytest). The secondary antibody was for all 
Western blots goat-anti mouse peroxidase (0.4 µg/mL; DAKO). S1 indicates serum sample of patient 1 
collected 12 hours after admission, [cTnT] = 14 µg/L; S2, serum sample of patient 2 collected 8 hours after 
admission, [cTnT] = 4.3 µg/L; P, positive control (troponin T-I-C complex spiked in cTnT-negative serum, 
[cTnT] = 2 µg/L); N, negative control (= cTnT-negative serum; [cTnT]<0.01 µg/L) 
 
 
SUPPLEMENTAL TABLE 1. Recoveries (%) of cTnT and cTnI in gel filtration chromatography 
 
 
 
 
a, all recoveries were calculated as follows: 
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b, mean recovery of all 24 GFC analyses; c, mean recovery based on 12 of the 24 GFC analyses 
 
 
Recovery (%) a cTnT cTnI 
Troponin T-I-C 96% 79% 
Purified cTnT 89% - 
Purified cTnI - 79% 
AMI patients 77% b 99% c 
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SUPPLEMENTAL TABLE 2. Baseline characteristics of AMI patients (n = 18) in which the molecular forms of 
cTnT were investigated at standardized time-points (0-72 hours after hospital admission). 
a, indicates coronary artery in which stent was placed;  b, time between symptom onset and hospital 
admission (hours:minutes), c, the maximum ST segment elevation during Holter electrocardiography; d, 
infarct size percentage measured with late gadolinium enhancement MRI; F, indicates female; M, male; RCA, 
right coronary artery; LAD, left anterior descending artery; mV, millivolt; U, units; n.a., not available 
 
 
 
 
N° Sex 
Age 
(yrs) 
Lesiona 
∆ time symptom onset 
and admission 
(h:min) b 
ST max 
(mV)c 
MRI  
(%)d 
1 F 66 RCA prox 4:07 -3.8 18.3 
2 M 56 RCA dist 2:35 6.9 27.6 
3 M 78 RCA mid 2:42 7.9 n.a. 
4 M 58 RCA prox 1:55 7.1 25.8 
5 M 52 RCA mid 2:17 2.8 22.0 
6 F 70 RCA prox 5:30 5.1 10.5 
7 F 50 LAD mid 4:09 4.9 23.2 
8 M 55 LAD prox 2:12 9.6 36.9 
9 M 58 LAD mid 5:30 5.4 0.8 
10 F 74 LAD mid 2:12 n.a. 24.5 
11 F 66 RCA mid 2:00 2.0 5.0 
12 M 54 RCA prox 3:30 3.3 10.3 
13 M 64 LAD prox 3:45 14.4 n.a. 
14 M 66 RCA prox 3:15 7.6 25.4 
15 F 48 LAD mid 4:00 8.8 n.a. 
16 M 44 RCA prox 4:30 n.a. 19.9 
17 M 61 RCA mid 2:15 6.4 21.3 
18 M 72 RCA prox 0:45 -1.9 2.5 
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Abstract     
Background 
Cardiac troponin T (cTnT) is known to be chronically elevated in patients with 
end-stage renal disease (ESRD), which is attributed to the presence of cardiac 
disease but also renal dysfunction. To date it remains unknown whether these 
chronically elevated cTnT concentrations reflect the accumulation of degraded 
or intact cTnT molecules. 
Methods 
By gel filtration chromatography (GFC), retention volumes for purified standards 
(cTnT-I-C complex and intact cTnT) and the  clinical assay’s quality control 
materials were investigated.  Additionally, GFC profiles of acute myocardial 
infarction (AMI) patients’ sera were determined. Eluates were subjected to 
immunoprecipitation and Western blotting, employing antibodies from the Roche 
immunoassay to mimic the clinical cTnT assay. Also, AMI patients sera were 
subjected directly to immunoblotting using either the detector antibody of the 
clinical assay or an antibody directed against the N-terminal end of cTnT. The 
validated GFC analysis was then applied to the sera from ESRD patients before 
and after hemodialysis (n= 10) and over 2 months follow-up (n=6) to establish 
the molecular forms of cTnT.  
Results 
Retention volumes (VR) of cTn T-I-C complex and intact cTnT were found to be 
20 and 27.5 mL, respectively. Also in quality control materials, cTnT eluted at 
27.5 mL. AMI patients’ sera revealed two cTnT peaks with retention volumes of 
27.5 and 45 mL, and Western blotting illustrated that these peaks corresponded 
to N-terminal truncated cTnT fragments of 29 and <18 kDa, respectively. In 
contrast to AMI, ESRD patients demonstrated only one reproducible cTnT-peak 
at 45 mL in serum samples obtained before as well as after hemodialysis. 
Moreover, this cTnT-peak remained stable following 2 months in time. This 
cTnT-peak could be allocated to the low-molecular weight cTnT fragments (<18 
kDa) in which the N-terminal end was found to be absent.  
Conclusion 
This is the first study to clearly demonstrate the presence of only degraded 
cTnT forms in the ESRD patients’ sera. Moreover, these cTnT-fragments were 
observed before and after hemodialysis, and were found to be stable over time.   
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Introduction 
The release of cardiac troponins (cTn) in the patient’s circulation is considered 
to be a hallmark for myocardial damage because of their unique 
cardiospecificity. The diagnosis of an acute myocardial infarction (AMI) 
therefore relies on an increase or decrease in serial cTn measurements, 
preferably performed with high-sensitvitiy cTn (hs-cTn) assays [1]. Previously, 
we have demonstrated in serial AMI patients’ sera that cTnT is degraded in a 
time-dependent pattern [2]. During the first hours after presentation at 
emergency department (ED), predominantly 29 kDa cTnT-fragments were 
present, while later on (>24 h after ED-presentation) only fragments <18 kDa 
were detected. 
Chronically elevated cTnT concentrations are also common in patients suffering 
from renal dysfunction [3-5]. The presence of measurable cTnT concentrations 
in these patients have been associated with abnormal left ventricular 
morphology and function [6], myocardial stunning [7], and with a higher risk on 
future cardiovascular events and mortality [8, 9]. Apart from this, significant 
associations between cTnT and renal clearance have been demonstrated [10]. 
It has been shown that these chronically elevated cTn concentrations reflect the 
accumulation of cTnT-fragments, as illustrated with Western blotting employing 
different antibodies than those of the clinical cTnT assay [11]. However, these 
findings have been opposed by others, who found only intact cTnT when 
analyzing the serum of ESRD patients with gel filtration chromatography (GFC) 
[12]. To date it is therefore contradictory which cTnT forms circulate in the 
serum of ESRD patients and which are detected by the clinical (Roche) cTnT 
assay. Gaining insight into the molecular forms of cTnT following ESRD, will 
further improve our understanding on the nature of chronic versus acute cTnT 
elevations.  
In this study, we therefore aim to elucidate the cTnT forms that are detected in 
the circulation of patients on hemodialysis using the clinical antibodies in a 
similar approach as previously performed in AMI patients [2], and as described 
in chapter 6 of this thesis. 
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Materials and Methods 
Study populations 
Molecular forms of circulating cTnT were assessed in the serum samples of two 
ESRD-populations, both on chronic hemodialysis therapy. In a first ESRD 
cohort of 10 patients, serum samples were drawn before and immediately after 
hemodialysis. In a second cohort of 6 patients, pre-dialysis serum samples were 
collected at baseline and 2 months later. All samples were immediately frozen 
at -80°C upon analysis. Both studies were conducted according to the principles 
of the Declaration of Helsinki and approved by the local ethics committees. 
Informed consent was obtained from all patients.  
Biochemical testing 
cTnT-concentrations were determined using the hs-cTnT assay (Roche 
Diagnostics) with a limit of detection at 5 ng/L and 10% CV cutoff at 13 ng/L. 
NT-proBNP was measured with a limit of detection at 5.08 ng/L (0.6 pmol/L) and 
CV 6.8% at 74.4 ng/L (8.78 pmol/L). Albumin was analyzed using the 
microalbumin assay with measuring range of 2.0-970 mg/L. All measurements 
were performed on the COBAS 6000 analyzer (Roche). 
Fractionation by GFC 
GFC was performed on the AKTA Prime Plus (GE Healthcare) equipped with a 
1.6x60 cm Sephacryl-S300 column (GE Healthcare). The column was 
equilibrated with 0.26 mol/L NaCl, 2.5 mmol/L CaCl2 ∙ 2 H2O, 0.02 mol/L Tris, 6 
mmol/L NaN3 and 1 g/L bovine serum albumin buffer, pH 7.4 [13] and operated 
at 0.5 mL/min. The void volume (V0) determination and calibration was 
conducted using the Gel Filtration Calibration kit (GE Healthcare) containing 
Dextran Blue (molecular weight (MW), 2000 kDa), conalbumin (MW, 75.0 kDa), 
ovalbumin (MW, 43.0 kDa), carbonic anhydrase (MW, 29.0 kDa) and 
ribonuclease (MW, 13.7 kDa). Dextran Blue (1 mg/ml) and globular protein 
standards (3-4 mg/ml) were dissolved in running buffer, 0.5 mL was loaded on 
the column, and absorbance was detected at 280 nm, all in duplo. V0 was 
determined to be 40 mL. 
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For GFC analysis, purified human cTn T-I-C complex (MW, 77 kDa; Hytest) and 
purified free cTnT (MW, 37 kDa, respectively; Hytest) were diluted in running 
buffer or spiked in serum pool of healthy volunteers (cTnT<14 ng/L). Calibration 
(level-2) and control (TN2) materials of the clinical Roche hs-cTnT assay were 
dissolved as prescribed by the manufacturer and immediately examined using 
GFC. Also residual serum of acute myocardial infarction patients were analyzed 
to validate previous results [2].  
To obtain the standard calibration curve, the gel-phase distribution coefficient 
(Kav= VR/(Vc-V0) ) was plotted against the logarithm of MW of globular proteins 
and purified cTn standards following the equation y=-0.34x+1.04. VR signifies 
the retention volume adjusted to void volume, while Vc indicated column volume 
and corresponded to 120 mL.  
For serum samples, 1.0-2.0 mL was loaded on the column. Serum albumin (67 
kDa) and serum NT-proBNP were used as internal standards in the patients’ 
sera. For each sample loaded, fractions of 1.25 mL were collected, kept on ice 
until immunoassay measurements (within 1 hour) and subsequently stored at -
80°C.  
Purification and Western blot detection of cTnT 
Purification and characterization of cTnT was performed using the antibodies 
from the Roche cTnT-assay (as kindly provided by Roche Diagnostics, 
www.roche.com). The capture cTnT antibody (M11.7, epitope a.a.r. 136-147) 
was used for immunoprecipitation of cTnT. To each mL of magnetic 
streptavidin-coated dynabeads (Invitrogen) 10 µg biotinylated M11.7 was 
added. Additionally, beads were crosslinked three times with dimethyl 
pimelimidate. Subsequently, 200-700 µL of serum was precipitated with 50 µL of 
M11.7-coated beads for 1 hour at 4°C. The average cTnT yield after 
immunoprecipitation was >90% (data not shown). After being washed with PBS 
containing 0.1% Tween-20 (PBST) the immunoprecipitates were eluted with 1 M 
glycine (18 µL), pH 3 for 15 min at 56°C.  
As negative controls for immunoblotting of GFC samples and AMI patients’ sera, 
running buffer or the serum pool of healthy volunteers was used, respectively. 
As positive controls, purified intact cTnT was spiked in running buffer and cTnT 
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negative pooled serum, respectively. Only GFC fractions containing sufficiently 
high cTnT concentrations (~500 ng/L) could be visualized on the immunoblot. 
Immunoprecipitates were diluted with XT Sample Buffer (6 µL) (Bio-Rad 
Laboratories), reduced at 56°C, and separated on a 12% Criterion XT SDS-
PAGE gel (Bio-Rad) together with the Precision Plus Protein Standard (Bio-
Rad). After stacking for 15 min at 100 V the proteins were resolved for 45 min at 
200 V in XT MOPS electrophoresis buffer (Bio-Rad) and were transferred to the 
nitrocellulose membrane (Bio-Rad, 0.45 µm) at 100 V for 1 h at 4°C. The 
membranes were treated with the vacuum SNAP i.d. protein detection system 
(Millipore) according to manufacturer instructions. Non-specific binding was 
blocked with 0.5% non-fat dry milk Blocking-Grade Blocker (Bio-Rad) in PBST. 
Primary antibodies were Roche M7 anti-cTnT (epitope a.a.r. 125-131; 10 µg/L), 
and cTnT-specific antibodies against the middle region (Hytest, 1C11, epitope 
a.a.r. 95-181; 7 µg/L) and the  N-terminal  region (Hytest, 9G6; epitope a.a.r. 1-
60;1 µg/L). As the secondary antibody, goat anti-mouse peroxidase (0.4 µg/mL; 
DAKO) diluted in PBST were employed. Subsequently, membranes were 
incubated in Super Signal West Femto Substrate (Thermo Scientific) and bands 
were detected using the ChemiDoc XRS scanner (Bio-Rad) and Quantity One 
Software (Bio-Rad, Version 4.6.5.).  
 
Results 
GFC analysis of control and calibration material for clinical assay 
GFC-analysis of purified cTn standards (cTn T-I-C complex, intact cTnT) spiked 
in cTnT-negative serum revealed adjusted retention volumes (VR) of 20 and 
27.5 mL, respectively (FIGURE 1A and B). Both standards eluted before the 
internal standard serum albumin (VR = 32.5 mL) and NTproBNP (VR = 45 mL). 
Western blotting of these GFC fractions using the clinical cTnT antibodies, 
confirmed that these two peaks both contain intact cTnT forms (estimated MW, 
MWest of 40 kDa; data not shown) as previously described [2].  
Furthermore, GFC-elution profiles of the control (TN-2; cTnT = 1921 ng/L) and 
calibrator (level 2; cTnT = 5586 ng/L) material of the clinical hs-cTnT assay both 
revealed a cTnT-peak at 27.5 mL (FIGURE 1 C and D respectively). 
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FIGURE 1. cTnT-peak profiles obtained by GFC analysis of purified cTn-T-I-C complex (A), purified intact cTnT 
(B), Roche clinical assay control (C) and calibration (D) material. In grey, retention volumes of the internal 
serum standards are indicated. 
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Validation of N-terminal cTnT fragments in AMI patients’ sera. 
As depicted in FIGURE 2A, the two-peak elution profiles of residual AMI serum 
samples was validated as previously described [2]. Retention volumes of 27.5 
and 45 mL were established, eluting before and after the internal standard 
serum albumin (VR = 32.5 mL), respectively. Western blot analysis assigned the 
first cTnT peak (VR of 27.5 mL) as the 29 kDa (MWest)-degradation product of 
cTnT (FIGURE 2A, right panel). The second peak (VR=45 mL) was allocated to 
even smaller cTnT degradation products of MWest between 14 and 18 kDa.  
 
 
FIGURE 2. GFC profile of a representative AMI patient (A), followed by Western blot analysis using the Roche 
cTnT antibodies (B), 1C11 antibodies for the detection of the middle region of cTnT (C) and an antibody 
directed against the N-terminal end of cTnT (D). P, indicates positive control of intact cTnT spiked GFC buffer; 
M, marker and N, negative control. 
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Furthermore, direct immunoprecipitation of residual AMI sera followed by 
Western blotting using the clinical cTnT antibodies assay (Roche M7 antibody) 
validated the presence of these 29 kDa and <18kDa cTnT-fragments that were 
also observed in the first and second GFC peak respectively (SUPPLEMENTAL 
FIGURE 1, left panel). However, none of these fragments demonstrated 
immunoreactivity with the antibody directed against the N-terminal end of cTnT 
(SUPPLEMENTAL FIGURE 1, right panel).  
 
 
 
 
SUPPLEMENTAL FIGURE 1. Western blot analysis of AMI patients’ serum samples using either Roche M7 
(left) or the N-terminal cTnT (right) detection antibody. 1 – 3, indicates serum samples of 3 AMI patients; P, 
positive control containing intact cTnT spiked in serum; M, marker and N, negative control.  
 
 
Presence and stability of N-terminal truncated cTnT fragments in ESRD patients 
In the first ESRD population (N=10), median (IQR) hs-cTnT concentrations were 
68.1 (52.2-80.4) ng/L and 62.5 (43.5-79.0) ng/L pre- versus post-dialysis, 
respectively (SUPPLEMENTAL FIGURE 2), demonstrating a minor and non-
significant reduction in hs-cTnT concentrations following hemodialysis.  
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SUPPLEMENTAL FIGURE 2. Hs-cTnT concentrations measured in serum of  ESRD patients (n=10) before and 
after hemodialysis 
 
 
GFC-elution profiles of these serum samples indicated a reproducible peak at 
adjusted VR of 45 mL before and after conventional hemodialysis (Figure 3A and 
B).  Also in the GFC analysis, a non-significant reduction in cTnT-peak was 
observed post-hemodialysis. 
In the second ESRD population (N=6), pre-dialysis samples at baseline (median 
(IQR) hs-cTnT concentrations of 151.8(134.7-159.6) ng/L) and 2 months later 
(median (IQR) hs-cTnT concentrations of 131.8 (115.7-158.2) ng/L)  were 
analyzed (SUPPLEMENTAL FIGURE 3). Also here, GFC profiles could only 
distinguish a reproducible peak at 45 mL for both time-points (FIGURE 3C and 
D). 
 
 
 
SUPPLEMENTAL FIGURE 3. Hs-cTnT concentrations measured in pre-hemodialysis serum samples of  ESRD 
patients (n=6)  at baseline and 2 months later. 
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Discussion 
In the present study, we clearly demonstrate that chronic cTnT elevations 
measured in ESRD patients’ sera, only reflect degraded cTnT forms.  Moreover, 
these cTnT-fragments were observed before and after hemodialysis, and were 
found to be stable over time.   
By means of GFC analysis, we were able to distinguish ternary cTnT-I-C 
complexes from intact and degraded cTnT forms. Moreover, our technique 
could differentiate the 29 kDa cTnT fragment  from low-molecular weight (<18 
kDa) cTnT fragments. Only intact cTnT and the 29kDa cTnT form could not be 
completely separated, consequently requiring Western blotting analysis for 
further differentiation. Also, we confirmed earlier findings of a two peak cTnT 
profile following AMI, containing 29 kDa and <18 kDa cTnT fragments [2].  
In cases of ESRD, we repeatedly distinguished one cTnT-peak at 45 mL, 
corresponding to the second peak in AMI patients, that was allocated to small 
N-terminal truncated cTnT forms. These results therefore indicate that cTnT 
elevations merely reflect completely degraded cTnT fragments in cases of 
ESRD as previously suggested [11] and not intact cTnT as also assumed [12]. 
The truncation of the N-terminal end of cTnT has been described to occur in the 
intracellular environment of cardiomyocytes [14-16]. However, whether 
observed cTnT fragments presented in this study are formed intracellularly or 
extracellularly goes beyond the purpose of this study and merits further 
research. Furthermore, whether these low-molecular weight cTnT fragments still 
contain their C-terminus has yet to be explored. 
In a second ESRD cohort, similar cTnT fragments were found in serum samples 
drawn 2 months apart [4]. Unlike the time-dependent cTnT degradation pattern 
following AMI [2, 17], cTnT fragments in ESRD patients’ sera therefore seem 
more stable in time. Moreover, the composition of cTnT forms clearly differs 
between AMI and ESRD patients, mainly during the time frame of clinical 
diagnosis of AMI (<12 hours) [2]. Consequently, it would be interesting to 
assess whether future assays, focusing only on the 27.5 ml peak, would 
increase the diagnostic performance of troponin assays in predicting acute 
coronary syndromes in patients with ESRD, which currently relies on serial hs-
cTn measurements [18, 19].  
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Low-molecular weight cTnT forms were found predialysis and immediately after 
hemodialysis.  A minor but non-significant decrease following hemodialysis in 
the cTnT GFC-peak was distinguished. It is therefore expected that these low-
molecular weight cTnT-fragments are in all probability cleared by the kidneys or 
during renal replacement therapy. 
Monitoring the calibration and precision of the assay is necessary to ensure 
quality hs-cTnT measurements. As shown in the present study, the materials 
used for this purpose seem to contain only intact cTnT molecules. Therefore, 
these quality controls are clearly not representative for ESRD and AMI patient’s 
serum. However, the magnitude of hs-cTnT measurements has still been 
described to be of prognostic value in ESRD [8, 9] as well as other populations 
[20-22]. It is therefore of utmost importance to investigate whether 
immunoreactivity changes for different cTnT forms and subsequently the 
detection of a mixture of cTnT forms could have implications for the clinical 
assay [19, 23]. 
In conclusion, this is to the first study to conclusively reveal that low-molecular 
weight cTnT fragments (<18 kDa) are present in the serum of ESRD patients. 
Importantly, this is different from cTnT-forms are recognized by the clinical 
assay in the acute phase of AMI and in quality control materials.  
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There is a broad consensus regarding the use of cardiac troponins (cTn), either 
cTnT or cTnI, as the preferred biomarkers to identify acute myocardial infarction 
(AMI) [1]. Major analytical improvements to the cTn assays have resulted in 
more accurate and very sensitive information, giving rise to new opportunities. 
When measuring with high-sensitivity (hs-) assays, elevated hs-cTn 
concentrations were not solely detected in the context of AMI, but also in a 
whole range of other pathologies [2]. Due to this lack in disease-specificity, hs-
cTn results can therefore be confusing for clinicians, especially in the low 
measuring range. In order for patients to fully profit from the benefits that these 
improved assays have to offer, it is of utmost importance to increase our 
understanding on how to interpret hs-cTn results.  
The trouble with defining 99
th
 percentile upper reference limits 
The current definition of an AMI is based on the rise and/or fall in cTn 
concentrations with at least one value above the 99
th
 percentile upper reference 
limit (URL) of normal [1]. In order to reliably assess the 99
th
 percentile with a 
uncertainty of <5%, the guidelines recommend a minimum sample size of 300 
healthy subjects [3-5]. Furthermore, the reference population should be 
screened for the presence of cardiac diseases, ideally using cardiac imaging 
techniques. Also, due to a lack of harmonisation between cTn assays, 99
th
 
percentile concentrations should be established for each assay [6].  
Peer-reviewed literature on the real-life determinations of the 99
th
 percentile 
cutoff has been reviewed in chapter two. This chapter illustrates that variable 
selection criteria are used to define the reference population, and subsequently 
a wide range of 99
th
 percentile concentrations were found for each assay. 
Comparing these different reference populations, variations were identified in 
selection criteria, distribution of age and gender and the number of included 
individuals. Lack of attention regarding these issues can result in misleading 
decision cutoffs and can in this way influence clinical practice.  
The definition of a healthy reference population 
As described in chapter two, the concept of “healthy” varied between different 
publications, ranging from fully based on health questionnaires to extensive 
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screens using laboratory and imaging tests. Applying more stringent selection 
criteria can result in a significant reduction in the 99
th
 percentile concentration 
[7-11]. However, applying rigorous screening tests such as echocardiography to 
a large number of presumably healthy subjects can be difficult and costly. 
Therefore, renal dysfunction combined with elevations in natriuretic peptides 
measurements [8], and left ventricular abnormalities assessed by 
echocardiography [9, 12] were reported to have the most pronounced effects on 
the 99
th
 percentile URL. Importantly, in chapter three it has been emphasized 
that even decreases within a normal kidney function can affect hs-cTn 
concentrations. As to date, no clear definition on what constitutes a healthy 
reference population for the determination of hs-cTn cutoffs has been described 
[13]. 
The influence of age, gender and race 
Numerous publications, as illustrated in chapter two, include variable age and 
gender distributions within their reference cohort. Previous studies have 
demonstrated that males have significantly higher hs-cTn concentrations than 
females [8-12, 14], which is also displayed in chapter three. The rationale 
behind this could be that males have more heart tissue than females [15]. In 
chapter four, we showed that elevated hs-cTn concentrations are commonly 
found in the elderly even when contributing comorbidities were excluded. These 
findings extend recent literature on the significant influence of age  on hs-cTn 
concentrations [9, 16, 17] and further underline the need for gender and age-
specific cutoffs in clinical practice as recently reviewed [18]. Although, large 
clinical trials investigating the diagnostic benefits of using these specific cutoffs 
are still lacking [19]. 
How many healthy individuals should be included? 
When establishing the 99
th
 percentile concentrations, it appeared that many 
studies include less than 300 subjects (chapter two). Noticeably, in these small 
reference cohorts, subjects were more likely to be highly screened for the 
absence of cardiovascular diseases, whereas large reference populations were 
less rigorously screened (by means of health questionnaires). However, to 
ensure an accurate cutoff, enough patients should be included as the 99
th
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percentile concentration is extremely sensitive to outliers [5]. Importantly, when 
identifying gender and age specific cutoffs, at least 300 subjects should also be 
included in each subcategory [15]. 
Association of renal clearance and high-sensitivity cardiac troponins 
One of the most common pathologies, besides AMI, for elevated cTn 
concentrations includes chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) [2, 20]. In contrast to AMI, ESRD patients exhibit elevated hs-
cTn levels that are more stable over time [21, 22]. The explanation of these 
chronic cTn elevations is still incompletely understood, and subclinical cardiac 
diseases are the most obvious explanation. However, a recent study including 
patients with renal dysfunction but without acute coronary syndromes, hs-cTn 
concentrations were still elevated and highly associated to renal clearance [23]. 
This renal influence also becomes evident in the study described in chapter five, 
where the effect of hemodialysis and the more promising hemodiafiltration 
treatments on hs-cTn concentrations are investigated. In this chapter a 
significant reduction in hs-cTnT as well as hs-cTnI concentrations following 
hemodiafiltration is described, as measured in serum samples drawn before and 
after hemodiafiltration. When patients received conventional hemodialysis, 
however no significant reduction in both hs-cTn concentrations could be 
established. This difference can be attributed to the presence of convection in 
hemodiafilatrion and not hemodialysis, which is known to induce more uremic 
toxin removal from the patients’ circulation [24]. Together these data validate the 
hypothesis that cTn molecules are cleared by the kidneys. In principle, both cTn 
molecules are small enough to be filtered by the kidneys (37 and 24 kDa, 
respectively). For final elucidation, hs-cTn concentrations should however be 
measured in urine or dialysate samples, as reported for NTproBNP [25, 26]. Up 
till now, this remains difficult due to matrix effects and dilution of already very 
low serum cTn concentrations by urine or dialysate. Importantly, in mild CKD to 
ESRD patients, hs-cTn elevations should not be discarded as irrelevant, since 
they remain highly associated with increased risk of death and cardiovascular 
disease, even when adjusted for renal dysfunction [6, 27, 28].  
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As to date, the magnitude of the impact of decreased renal function on hs-cTn 
concentrations is unknown. In chapter three we increased our understanding on 
the cardiac and renal contribution to higher hs-cTnT and hs-cTnI concentrations 
in patients with chest pain, without any signs of renal disease. Herein, a 
significant inverse association between eGFR and hs-cTn was shown, which 
has also been established in other study populations [27, 29, 30]. Moreover, in 
chapter three, we revealed that the association with renal function was 
independent and stronger than with any measured CT parameters, such as 
CAD severity and coronary calcium score. Similar analyses were performed in 
an elderly population of nursing home residents (chapter four), with prevalent 
heart failure (~40%) and renal dysfunction (~54%). Also here, hs-cTn 
concentrations were highly associated with renal dysfunction even beyond the 
presence of heart failure. Together, these studies demonstrate that hs-cTn 
concentrations, especially hs-cTnT, reflect both renal and cardiac disease and 
subsequently both pathologies can greatly affect the 99
th
 percentile URL. 
Furthermore, these findings could offer an explanation why diagnostic cutoffs 
established in cardiac and renal healthy subjects have a reduced diagnostic 
performance in patients with renal dysfunction [31]. Therefore, further research 
should focus on the influence of renal dysfunction on cTn cutoff values and 
investigate whether adjusting cTn cutoffs for renal function is of clinical value or 
baseline hs-cTn results should be accompanied with renal function assessment.  
Proteolysis of cardiac troponin T 
Injury to the myocardium can result in the activation and release of proteolytic 
enzymes. For cTnI it is generally acknowledged that proteolysis following 
myocardial infarction results in the presence of different cTnI fragments in 
human serum [32-34]. This diversity in molecular forms of cTnI had serious 
implications for the harmonisation between different cTnI assays [34, 35]. Since 
all cTnI assays employed different antibodies that recognize different cTnI 
forms, up to 10-fold variation between cTnI-results assays could be observed. 
For this reason it is necessary that antibodies should recognize epitopes in the 
most stable parts of cTnI [34, 35], resulting in considerably less variations in 
cTnI nowadays.  
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In contrast to cTnI, degradation of cTnT upon myocardial infarction remained 
controversial. By means of Western blotting, but employing other antibodies as 
the clinical cTnT assay, the presence of degraded cTnT forms has been shown 
in serum of AMI patients [36, 37]. Also, in serum of ESRD patients, only cTnT 
fragments were found [23]. However, these results were disputed in studies 
using gel filtration chromatography (GFC), who found cTnT in serum of AMI [38] 
and ESRD patients [39] to be mainly in the intact or complexed form with cTnI or 
TnC. Therefore, a combination of GFC and Western blotting, using the same 
antibodies as the clinical assay, was utilized in chapter six and chapter seven to 
finally elucidate the cTnT forms that circulate in AMI and ESRD patients’ sera, 
respectively.  
Time-dependent degradation of cTnT 
In chapter six we demonstrate that a heterogeneous mixture of cTn  fragments 
was found in the blood of AMI patients and these fragments are identified with 
the clinical cTnT assay antibodies. It was shown that not intact cTnT, but the N-
terminal truncated form of cTnT, corresponding to a molecular weight of ~29 
kDa, was most abundantly present during the critical hours of diagnostic testing 
(<8 hours). Thereafter, smaller fragments ranging in size from 14-18 kDa 
appeared to circulate in AMI patients’ sera, validating the time-dependent 
degradation pattern that was previously described [36]. 
In chapter seven, we found in ESRD patients with chronic cTnT elevations that 
exclusively low-molecular weight fragments (<18 kDa) were present in the 
circulation. The same fragments were found for all ESRD patients (total of 17 
patients) in samples drawn at different timepoints (at 2 months of follow up and 
pre- versus post-dialysis). It should be noted that these ESRD patients were 
treated with conventional hemodialysis, which was shown in chapter five to not 
significantly influence hs-cTn concentrations pre- versus post dialysis. In 
contrast, a significant intradialytic decrease in hs-cTnT concentrations was 
shown following hemodiafiltration (chapter five). It would therefore be interesting 
to also examine cTnT-fragments that are present pre- versus post-
hemodiafiltration.   
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Implications for the clinical assay results 
Since, Roche Diagnostics is the only manufacturer of clinical cTnT assays, cTnT 
degradation does not affect harmonization between different assays. To ensure 
quality of the cTnT measurement in blood samples, the manufacturer 
recommends the use of recombinant human cTnT spiked in a human serum 
matrix for monitoring the calibration and precision of the assay.  However, as 
shown in this thesis, recombinant intact cTnT is not representative for AMI and 
ESRD patients’ serum, which was clearly shown to mainly contain cTnT 
fragments.  
It is currently unknown whether immunoreactivity of the assay is equal for 
different cTnT forms. It seems very likely that the assay response to the various 
troponin forms might differ and, consequently, will affect the performance of 
serial measurements [40]. Whether the time-dependent degradation pattern 
influences the diagnostic performance of cTnT, still needs further clinical 
evaluation [41].  
Nevertheless, in this thesis it was clearly shown that the most prevalent 
molecular forms differed between AMI (~29 kDa) and ESRD (<18 kDa) patients. 
These findings have led to the hypothesis that the cTnT assay could be 
improved by recognizing specific molecular cTnT forms, and thereby make a 
better differentiation between acute and chronic cTnT elevations.  
Intracellular or extracellular degradation of cTnT 
It still remains to be elucidated whether the observed degradation of cTnT 
occurs intracellular or extracellular of ischemic cardiomyocytes. Several in vitro 
studies have demonstrated that the degradation of cTnT occurred upon 
ischemia, due to the activity of either calpain-I [42-44] and caspase-3 [45] in the 
intracellular environment of cultured cardiomyocytes. This intracellular 
proteolytic activity is shown to result in a N-terminal truncated form of cTnT, that 
does not impair the function of cTnT but reflects an intracellular adaption to 
stress conditions [43]. In contrast, in vitro studies on metabolic deprived 
cardiomyocytes of primary cell cultures [46] and a contracting cell-line [47] have 
demonstrated that after cell death mostly intact cTnT and only minor fragments 
are detected in the medium of the cell culture. Current literature therefore 
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suggests not only a role for intracellular but also extracellular proteolytic activity. 
This all leads to the intriguing question of which modification patterns of cTn are 
present when myocardial necrosis is thought to be absent, for instance after 
physical activity. Moreover, understanding the mechanisms that result in these 
post-translational modifications of cTn can give further insights into the release 
of cTn from cardiomyocytes. 
Differences between cTnT and cTnI 
Throughout this thesis, hs-cTnT and hs-cTnI were measured simultaneously in 
different patient cohorts (TABLE 1). Interestingly, in each cohort we observed 
that median hs-cTnT concentrations were noticeably higher than hs-cTnI 
concentrations. This was consistent with data published in peer-reviewed 
articles who also investigated hs-cTnT and hs-cTnI concentrations in ACS and 
non-ACS patients (TABLE 2). On the other hand, in AMI patients hs-cTnI 
concentrations were found to be markedly higher than hs-cTnT and  were only 
moderately associated with each other (Pearson R~0.60) (TABLE 2) [48-51]. 
Despite the fact that differences between hs-cTnT and hs-cTnI have been 
described, no detailed analysis regarding the differences in chronic versus 
acute diseases is present to date. Moreover, according to the current guidelines, 
cTnT and cTnI results are considered interchangeably from each other [4]. 
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Release kinetics of cTnT versus cTnI molecules 
The release kinetics of cTnI have been described to deviate from cTnT in both 
earlier release [52] and decline [53] following myocardial damage. Namely, 
cTnT exhibits a second peak that has been allocated to a slower dissociation of 
cTnT molecules due to its structural bound to myofibrils, which is absent for cTnI 
[53, 54]. Whether also more cTnI molecules are therefore released upon 
myocardial damage is currently unknown. 
In chapter three and chapter four we observed that hs-cTnT was more strongly 
associated to renal dysfunction in comparison to hs-cTnI. In line with this 
finding, excluding patients with renal dysfunction had the most effects on hs-
cTnT in comparison to hs-cTnI (chapter four). More robust associations of eGFR 
with hs-cTnT in comparison to hs-cTnI have also been reported by others [8, 55] 
and generally there are more elevations reported for cTnT than cTnI in ESRD 
patients [21, 56]. Together, these findings evidence that hs-cTnT results are 
more susceptible to changes in renal function than hs-cTnI results. To our 
opinion, the second peak in the release curve of cTnT might therefore be 
attributed to the accumulation of cTnT molecules following a slower clearance 
from the system in comparison to cTnI. 
Additionally, in chapter five, it was found that the influence of hemodialysis 
differed between hs-cTnT and hs-cTnI concentrations. Although, it remains 
difficult to separate the effects of release and clearance on higher hs-cTn 
concentrations, hemodiafiltration was shown to have more effect on hs-cTnT in 
comparison to hs-cTnI. Structural differences between cTnT and cTnI can 
contribute to these dissimilarities as the molecular size of cTnI (24 kDa) is 
smaller than cTnT (37 kDa). Additionally, it is known that both proteins are 
degraded in the patients serum, resulting in a heterogeneous mixture of cTnT 
(<29 kDa, chapter six and chapter seven) and cTnI (<20 kDa; [32, 34]) 
molecules. Due to these structural differences, release from damaged 
myocardium [53] and transfer of cTnT and cTnI across the viable cell membrane 
may not be equal.  
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Prognostic value of hs-cTnT versus hs-cTnI concentrations 
Several large clinical trials have demonstrated that low hs-cTnT and hs-cTnI 
concentrations, even below the diagnostic cutoff, are associated with a higher 
risk on developing cardiovascular events and all-cause mortality, and even on 
top of traditional risk factors [30, 55, 57]. In chapter four, hs-cTnT was found to 
be a superior predictor for all-cause mortality in comparison to hs-cTnI. These 
findings have also been observed in the APACE trial, enrolling patients at  the 
emergency department with symptoms suggestive for AMI [58]. In these 
patients, risk on mortality was more accurately predicted by hs-cTnT than by hs-
cTnI. Similarly, in other populations such as ESRD [6], heart failure [59]  and 
ACS [60] patients, hs-cTnT was found to be a better predictor for all-cause 
mortality than cTnI assays. In line with these results, Omland and colleagues 
found that hs-cTnT and hs-cTnI can hold independent prognostic information to 
each other [55], questioning whether cTnT and cTnI are truly interchangeable 
risk predictors. The reasoning behind these observed differences is still 
speculative and could involve the stronger association of hs-cTnT with renal 
disease. Remarkably, for the prediction of cardiovascular disease these 
differences were less apparent than for all-cause mortality, as demonstrated in 
chapter three [58]. More studies involving both hs-cTnT as hs-cTnI assays 
should therefore be performed for final elucidation of these differences. 
Cardiospecificity of cTnT versus cTnI proteins 
Since the discovery of cTn proteins as cardiac biomarkers, it has been shown 
that the cardiac isoform of cTn is specifically expressed in cardiac muscle [61, 
62]. However, the cardiospecificity of cTnT, but not cTnI, has been questioned 
especially in patients with neuromuscular diseases [63]. In these patients, cTnT 
results were elevated whereas normal (<URL) cTnI concentrations were 
detected. In these studies, the rationale for this phenomenon was the re-
expression of the cardiac cTnT isoform in the skeletal muscles, resulting in 
false-positive cTnT elevations [64, 65]. In this thesis, we demonstrate that hs-
cTnT results are in general higher than hs-cTnI results. Moreover, elevated cTn 
concentrations are defined by the 99
th
 percentile upper reference limit, which is 
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highly dependent on the reference population and mostly reported to be lower 
for cTnT as for cTnI [15].  
Using western blotting it was shown that the Roche capture and detector 
antibodies are each capable of detecting cTnT in skeletal biopsies of patients 
with neuromuscular disorders [64]. However, to ensure minimal aspecific 
binding of the assay, the clinical cTnT assay encompasses the combination of 
the two antibodies. Due to the a kind collaboration with Roche Diagnostics, we 
did not found any aspecific binding towards skeletal forms of troponin T using 
Western blotting incorporating both clinical (capture and detection) antibodies. 
Also, hs-cTnT and hs-cTnI were shown to correlate equally as well to cardiac 
diseases such as AMI and heart failure. Therefore, no hard evidence is currently 
given to question the cardiospecificity of the cTnT assay. 
 
Conclusion 
It is apparent from data in the present thesis that the 99
th
 percentile is not a 
perfect diagnostic cutoff and has its limitations concerning the influences of age, 
gender and renal function of the cardio-healthy reference population. 
Noteworthy is that hs-cTn concentrations are no stand-alone tests and should 
always be interpreted in the clinical context together with clinical symptoms and 
additional diagnostic testing [1].  
Although the interpretation of hs-cTn results is complex, in this thesis we 
observed that both hs-cTnT and hs-cTnI concentrations are still highly 
associated with cardiac diseases and even very low  levels were valuable risk 
stratifying tools. Our results however also show that next to cardiovascular 
disease, hs-cTn concentrations, especially hs-cTnT, are highly associated with 
renal function as well.  
Furthermore, we clearly demonstrate that upon its release from the damaged 
myocardium, cTnT is degraded in a time-dependent manner, ranging from intact 
to low-molecular weight fragments, which are all recognized by the antibodies of 
the clinical assay (FIGURE 1). The smallest degradation products also 
accumulate in the circulation of ESRD patients, and in this form, cTnT 
molecules are presumably cleared from the circulation (FIGURE 1).  
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FIGURE 1. Following myocardial damage, cTn molecules are released into the blood stream. In the patients’ 
circulation, degraded cTnT (chapter seven and eight) and cTnI [33] forms have been detected. We 
hypothesize that these low-molecular weight cTnT and cTnI fragments will eventually be cleared from the 
circulation via the kidneys. However, these influences are complicated by the fact that release and clearance 
of cTn are simultaneous processes and cardiac and renal disease can aggravate each other.  
 
 
Finally, we observed remarkable differences between hs-cTnT and hs-cTnI 
concentrations in all our clinical populations, seriously questioning whether 
these results are truly interchangeable from each other. Future work should 
illustrate in more detail if a combination of both cTnT and cTnI testing can have 
added diagnostic value in more complex cases. 
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Summary 
The diagnosis of acute myocardial infarction (AMI) is based on the release of 
cardiac troponins (cTn) in the bloodstream. Major analytical improvements to 
the clinical assays have led to more accurate and very sensitive information 
regarding cTn. However, the current high-sensitivity tests for cTnT (hs-cTnT) 
and cTnI (hs-cTnI) also resulted in the detection of elevated concentrations in 
patients with diseases other than AMI, such as heart failure, and renal 
dysfunction. This complicates the application of the assay and it is therefore of 
utmost importance to increase our understanding on how to interpret hs-cTn 
results, especially in the low-measuring range. 
The diagnostic cTn cutoff for myocardial infarction is set at the 99th percentile 
upper reference limit (URL) of a healthy reference population. An overview of 
peer-reviewed literature on the real-life determinations of the 99th percentile 
cutoff is given in chapter two. This chapter illustrates that variable selection 
criteria are used to define the reference population, and subsequently a wide 
range of 99th percentile concentrations were found for each assay. Lack of 
attention regarding these issues can result in misleading decision cutoffs and 
can in this way influence clinical practice. 
The association between kidney function and cTn concentrations has been 
described, although it is currently unclear whether chronic cTn elevations reflect 
chronic release due to cardiac damage or they are also the result of a 
decreased renal clearance. In chapter three, we therefore examined the extent 
that renal function contributes to higher cTn concentrations in patients with 
chest discomfort, in whom circulating troponins are mainly attributed to the 
presence and severity of atherosclerotic plaques or echocardiographic 
abnormalities. Remarkably, we revealed that the association with renal function 
was independent and stronger than with any measured CT parameters, such as 
CAD severity and coronary calcium score. Similarly, in an elderly population of 
nursing home residents (chapter four), with prevalent heart failure (~40%) and 
renal dysfunction (~54%), hs-cTn concentrations, especially hs-cTnT, were 
highly associated with renal dysfunction even beyond the presence of heart 
failure. Together, these studies demonstrate that hs-cTn concentrations are 
highly and independently associated with both renal as cardiac diseases and 
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subsequently both pathologies can greatly affect the 99th percentile URL. 
Consequently, the interpretation of baseline hs-cTn concentrations might be 
improved when accompanied with the assessment of renal clearance. 
End-stage renal disease (ESRD) patients often exhibit elevated cTn levels that 
are more stable over time. To date, it remains unclear how dialysis affects cTn 
results, as both intradialytic increases and decreases have been reported. 
Chapter five is the first study to reveal the effects of extended hemodialysis and 
hemodiafiltration on cardiac markers and describes a significant reduction in hs-
cTnT as well as hs-cTnI concentrations following hemodiafiltration.  
Furthermore, there is evidence that cTn proteins are also subjected to 
posttranslational modifications, such as degradation. Which circulating cTnT 
forms are detected by the clinical assay in the blood of AMI and ESRD patients 
is investigated in chapter six and chapter seven, respectively. In chapter six, we 
show that, upon its release from the damaged myocardium, cTnT is degraded in 
a time-dependent manner, ranging from intact to low-molecular weight 
fragments. The smallest degradation products also accumulate in the circulation 
of ESRD patients (chapter seven). In this thesis, it was therefore clearly shown 
that the most prevalent molecular forms differed between AMI (~29 kDa) and 
ESRD (<18 kDa) patients. It would therefore be interesting to investigate 
whether the clinical assay can be improved by detecting specific molecular 
cTnT forms.  
Finally, throughout this thesis, hs-cTnT and hs-cTnI concentrations have been 
measured in various acute and non-acute settings, and we observed 
remarkable differences between hs-cTnT and hs-cTnI concentrations in all 
clinical populations, discussed in chapter eight. This seriously questions  
whether hs-cTnT and hs-cTnl results are truly interchangeable from each other. 
Future work should illustrate in more detail if a combination of both cTnT and 
cTnI testing can have added diagnostic value in more complex cases. 
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Samenvatting 
De diagnose van een acuut hartinfarct berust op de vrijzetting van cardiale 
troponines (cTn) in de bloedbaan. Door de ontwikkeling van meer accurate en 
gevoeligere cTn testen, zijn er steeds meer mensen waarbij cTn-verhogingen 
worden gedetecteerd. De huidige hoge gevoeligheidstesten voor cTnT (hs-
cTnT) en cTnI (hs-cTnI) tonen aan dat beide testen ook verhoogd zijn bij 
patiënten met een andere pathologie als een myocardinfarct, zoals bijvoorbeeld 
bij hartfalen en renale dysfunctie. Dit alles bemoeilijkt het gebruik van de assay 
en roept vragen op over de interpretatie van cTnT en cTnI resultaten, vooral in 
het lage meetbereik. 
De diagnostische afkapwaarde voor een myocardinfarct wordt gedefinieerd als 
de 99ste percentiel concentratie, gemeten in een gezonde referentiepopulatie. 
Een overzicht van de gepubliceerde literatuur over de werkelijke bepaling van 
deze 99ste percentiel afkapwaarde is weergegeven in hoofdstuk twee. Dit 
hoofdstuk illustreert dat in elke studie andere selectiecriteria gebruikt werden 
om de referentiepopulatie te definiëren. Dit heeft als gevolg dat steeds 
verschillende afkapwaarden gevonden werden voor éénzelfde assay. Gebrek 
aan aandacht voor deze verschillen kan resulteren in misleidende 
afkapwaarden en kan op deze manier de klinische diagnose beïnvloeden. 
Dat er een associatie is tussen de nierfunctie en cTn-concentraties is reeds 
beschreven. Toch is momenteel niet geweten of deze chronische verhogingen 
het gevolg zijn van een ophoping van cTn moleculen door een gedaalde 
nierklaring of dat het om cardiale schade gaat. In hoofdstuk drie is daarom 
onderzocht in welke mate nierfunctie bijdraagt tot hogere cTn-concentraties bij 
patiënten met pijn op de borst. In deze populatie worden gedetecteerde cTn-
waarden immers toegeschreven aan de aanwezigheid en ernst van coronaire 
atherosclerosis of echocardiografische afwijkingen. Opmerkelijk is dat in deze 
studie wordt aangetoond dat de associatie met de nierfunctie onafhankelijk en 
sterker was dan de associatie met CT-parameters, zoals de ernst van de 
atherosclerose en een hoge coronaire calcificatie score. In een populatie van 
fragiele verpleeghuisbewoners (hoofdstuk vier), met een hoge prevalentie van 
hartfalen (~40%) en nierfunctiestoornissen (~54%), wordt dit ook duidelijk. Hier 
tonen we aan dat hs-cTn concentraties, met name hs-cTnT, zeer sterk 
SAMENVATTING 
 
179 
 
geassocieerd zijn met een gedaalde nierfunctie, onafhankelijk van de 
aanwezigheid van hartfalen. Samen laten deze studies zien dat hs-cTn 
concentraties niet enkel hart- maar ook nieraandoeningen kunnen 
weerspiegelen en dat vervolgens beide pathologieën een grote invloed hebben 
op de 99
ste
 percentiel afkapwaarde. Bijgevolg zou de interpretatie van hs-cTn 
concentraties kunnen worden verbeterd wanneer zij gecombineerd worden met 
een schatting van de renale klaring. 
Patiënten aan dialyse vertonen vaak verhoogde cTn resultaten die meer stabiel 
zijn over de tijd. Tot op heden blijft onduidelijk hoe dialyse de cTn resultaten kan 
beïnvloeden, gezien zowel cTn stijgingen als dalingen gemeten worden na 
dialyse. Hoofdstuk vijf is de eerste studie die de effecten van langere 
hemodialyse- en hemodiafiltratie-behandeling onderzoekt. Deze studie laat zien 
dat een significante daling in hs-cTnT en hs-cTnI concentraties aanwezig is na 
hemodiafiltratie. 
Tevens is er bewijs dat cTn eiwitten ook post-translationele modificaties, zoals 
degradatie, kunnen ondergaan. De verschillende cTnT vormen, in het bloed van 
hartinfarct en dialyse patiënten, die gedetecteerd kunnen worden door de 
huidige klinische assay worden onderzocht in respectievelijk hoofdstuk zes en 
hoofdstuk zeven. In hoofdstuk zes tonen we aan dat na een myocardinfarct, 
cTnT gedegradeerd voorkomt in het bloed. Deze degradatie gebeurt in een 
tijdsafhankelijke patroon, waarbij eerst intact en vervolgens laag moleculaire 
cTnT-fragmenten gedetecteerd worden. In hoofdstuk zeven wordt echter 
bewezen dat in de bloedcirculatie van dialyse-patiënten enkel deze kleine 
afbraakproducten aanwezig zijn. In dit proefschrift wordt daarom duidelijk dat de 
gedetecteerde moleculaire cTnT-vormen gedurende de eerste uren na een 
hartinfarct (~ 29 kDa) verschillen van dialyse-patiënten (<18 kDa). Het zou 
daarom zeer interessant zijn om te onderzoeken of de huidige cTnT-test 
verbeterd kan worden door specifiekere cTnT-vormen te detecteren, zoals het 
29-kDa fragment. 
Tot slot werd in dit proefschrift hs-cTnT en hs-cTnI gemeten in diverse 
populaties met acute en niet-acute pathologieën. Hierbij zagen we opmerkelijke 
verschillen tussen hs-cTnT en hs-cTnI, zoals bediscussieerd in hoofdstuk acht. 
Deze bevindingen stellen daarom in vraag of de resultaten van de cTnT en cTnI 
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assays daadwerkelijk uitwisselbaar zijn van elkaar. Verdere studies moeten in 
meer detail uitwijzen of een combinatie van beide testen een diagnostische 
meerwaarde kunnen betekenen in patiënten met meer complexere 
ziektebeelden. 
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Valorisation 
Economic and Social Relevance 
Cardiovascular diseases (CVD) are a major cause of death with a mortality rate 
of approximately 30% across Europe and America [1, 2]. CVD covers a wide 
range of disorders, including diseases of the cardiac muscle and of the vascular 
system. The majority of CVD that lead to mortality are due to acute myocardial 
infarction (AMI) and stroke. Cardiovascular research has already resulted into 
more interventions with significant reductions in morbidity and mortality [3, 4]. 
Regardless of this decline in mortality, more patients are at cardiovascular risk 
due to increased life expectancy and comorbidities related to an unhealthy 
lifestyle. Clinical care of these patients is already costly and is expected to 
further increase in the future. Additionally, treatments may also tremendously 
impact the quality of life of these patients. Future research should therefore 
focus on prevention and earlier detection of heart diseases.  
Cardiac troponins are an essential component of the diagnostic criteria for 
myocardial infarction, especially when electrocardiographic results are 
inconclusive. According to the current guidelines a rise and/or fall in cardiac 
troponin (cTn) T or I concentrations, with at least one value above the 99
th
 
percentile of a healthy reference population, signifies myocardial damage and 
must be accompanied with also clinical indications such as ischemic symptoms 
or imaging evidence of myocardial damage [5]. 
Increasingly sensitive cTn assays enable an earlier diagnosis but severely 
impair the specificity towards AMI. When measuring with high-sensitivity (hs-) 
assays, elevated hs-cTn concentrations were also detected in a whole range of 
other pathologies [6]. Due to this lack in disease-specificity, unravelling the 
causes of hs-cTn positive results can therefore be challenging, especially in 
patients affected by more than one disease. 
On the contrary, the increases in analytical sensitivity also gave rise to new 
opportunities for these assays. Even below the diagnostic cutoff, higher hs-cTn 
values are strongly associated with an increased risk on cardiovascular 
diseases and mortality, making them promising risk stratifying tools [7, 8]. 
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Target groups 
Cardiac troponins are important and highly used cardiac markers and their 
results are mainly interpreted by clinicians and laboratory specialists. Even 
before the publication of the current guidelines [5], a European survey 
demonstrated that 59% of the inquired laboratories were using cTnT or cTnI 
concentrations to diagnose AMI [9]. Results presented in this thesis can guide 
clinicians and laboratory specialists to a better understanding of hs-cTn results, 
by gaining insight into important clinical questions such as changes in  renal 
clearance can affect hs-cTn results. Eventually a better interpretation of hs-cTn 
results can lead to an earlier diagnosis or rule out of patients. These 
advancements all have the potential to lead to more efficient, better and cost 
effective diagnostic process. 
 
Activities and/or products 
The results described in this thesis can be used for the development of various 
products or tools. 
In this thesis we show that elevated cTn, especially hs-cTnT, concentrations 
were detected in elderly people without any evidence of heart and kidney 
diseases. These results support the concept that also other clinical indicators, 
besides acute myocardial damage, can greatly influence baseline hs-cTn 
results. As such, when considering individuals with non-acute symptoms, a 
young female individual without any cardiac history and a normal renal 
clearance will have lower baseline cTn concentrations as compared to an older 
male individual with decreases in renal clearance. For this reason, applying 
generalized cutoffs can result in under- or over-diagnosis within different patient 
cohorts [10-12], already implying that it is of great importance to interpret hs-cTn 
results to a more individual level. The development of a clinical alghorithm might 
therefore be helpful to give direction of which hs-cTn result to expect in a 
patient, taken into account important factors (such as age, gender,  
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cardiovascular history, renal clearance, timing of blood collection, precision of 
the assay, etc.) Current guidelines also indicate the advantage of measuring 
more than one cTn concentration in time, although it remains unclear which 
delta to use for a safe rule out of a patient [5, 13-15]. Also here, a clinical 
algorithm might be helpful for a better indication what constitutes a significantly 
increased value that requires further clinical examinations. 
Although cTn results are currently not used in the clinic to indicate the risk on 
future cardiovascular diseases and mortality, all current literature undeniably 
shows that higher troponin concentrations are significantly associated with the 
incidence of such a risk [16]. It seems therefore quite logic that hs-cTn results 
should be implemented in clinical risk scores that can be used in patients at risk 
for cardiovascular diseases. Potentially these clinical risk scores can serve 
guidance for preventive therapies in patients at high risk. 
Furthermore, measuring multiple biomarkers have been proposed in the 
management of acute coronary syndromes. The combination of cTn 
measurements with more traditional biomarkers (C-reactive proteins, 
NTproBNP) and newly developed biomarkers (such as copeptin, heart-type fatty 
acid-binding protein) are widely investigated [17-19]. In this thesis, preliminary 
data shows that combining hs-cTnT and hs-cTnI assays might also be 
promising to further enhance the diagnostic potential of cardiac troponins.  
We are the first to clearly show that the most prevalent molecular cTnT forms 
detected by the clinical cTnT assay are fragments. Moreover, different cTnT 
forms were observed during the early acute cTnT release following AMI (~29 
kDa) as compared to chronic elevations seen in  ESRD (<18 kDa) patients. New 
and unpublished results show that larger cTnT forms (≥29 kDa) still contain their 
C-terminal end, while the smaller fragments (<18 kDa) do not. This thesis 
therefore indicates that targeting the larger cTnT fragments have the potential to 
enhance the disease-specificity of the clinical assay. Adding a third antibody, 
directed against the C-terminal region of cTnT, to the current clinical ELISA 
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method can detect the proportion of these larger cTnT fragments, as illustrated 
in FIGURE 1. Future research has to indicate whether such a test can be used 
in addition to the current clinical hs-cTnT test, and might lead to a better 
differentiation between acute and chronic cTnT elevations.  
 
 
FIGURE 1. A. Conventional cTnT testing according to the ELISA method of the clinical assay. B. Incorporation of a third cTnT 
antibody directed against the C-terminal end. 
 
Implementation in clinical practice 
Cardiac troponins are already incorporated in clinical practice. Results obtained 
in this thesis show promising new opportunities for this biomarker in the clinic. 
Over the past years, increasingly more research is performed on the 
determinants and risk-stratification of hs-cTn results. However, specific 
algorithms incorporating more clinical indicators for high hs-cTn results are 
currently not available and still need to be developed. Also, many clinical scores 
have already been developed for the prediction of adverse events in high-risk 
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patiens with ACS [20, 21], low-risk patients with symptoms of chest pain [22, 23] 
and even more general populations [24, 25]. However, most of these risk scores 
do not include hs-cTn results. Up till now, only one risk algorithm incorporates 
cTn concentrations when determining the risk in patients presenting with chest 
pain at the emergency department [23], which is still validated in the clinic trials. 
Whether hs-cTn concentrations can further improve these  risk scores, also in 
more general populations, still merits further research. 
Furthermore, the development of a new assay entails careful validation of the 
quantification, linearity and specificity of the results. To ensure the detection of 
cardiospecific cTnT isoforms, we propose the inclusion of a third antibody to the 
current hs-cTnT assay. For this reason, this new method must  be developed in 
close collaboration with the manufacturer of the current hs-cTnT test (Roche 
Diagnostics). 
Once these advancements are developed, the added value should be monitored 
in prospectively randomized control studies. Eventually, correct implementation 
of these tools requires that specialists should be educated on how to interpret 
the results through scientific exposure (peer-reviewed publications or 
international congresses) and guideline documents that are published by 
national and international societies in cardiology  and biochemistry. 
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Abbreviations 
AMI   acute myocardial infarction 
CAD   coronary artery disease 
cTn   cardiac troponin 
cTnT   cardiac troponin T 
cTnI   cardiac troponin I 
TnC   troponin C 
hs-cTn   high-sensitivity cardiac troponin 
hs-cTnT  high-sensitivity cardiac troponin T 
hs-cTnI   high-sensitivity cardiac troponin I 
ECG   electrocardiography 
STEMI   ST-elevation myocardial infarction 
NSTEMI  non-ST elevation myocardial infarction 
URL   upper reference limit 
CV   coefficient of variation 
CKD   chronic kidney disease 
ESRD   end-stage renal disease 
ACS   acute coronary syndromes 
LoB   limit of blank 
LoD   limit of detection 
RCV   reference change value 
CVD   cardiovascular disease 
CCTA   cardiac computed tomographic angiography 
CCS   coronary calcium score 
eGFR   estimated glomerular filtration rate 
LVH   left ventricular hypertrophy 
LVEF   left ventricular ejection fraction 
IQR   interquartile range 
ROC   receiver-operating curve 
AUC   area-under-the-curve 
CI   confidence interval 
CABG   coronary artery bypass graft  
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PCI   percutaneous coronary intervention 
NTproBNP  N-terminal fragment of the prohormone brain-type  
   natriuretic peptide 
OR   odds ratio 
HR   hazard ratio 
HD   hemodialysis 
HDF   hemodiafiltration 
RR   reduction ratio 
GFC   gel filtration chromatography 
CK   creatine kinase 
LD   lactate dehydrogenase 
MW   molecular weight 
V0   dead volume 
VR   retention volume 
Kav   gel-phase distribution coefficient 
ED   emergency department 
PBS   phosphate buffered saline 
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